 
Page 1 
  
 
 
 
Clinical Protocol  
 
 
A Phase 2, Randomized, Double -Blind, Placebo -Controlled Study of the Safety and 
Efficacy/Potency of a Single Dose of Xisomab 3G3 , Administered at the Beginning of a 
Regular Hemodialysis Procedure , in Patients with End -Stage Renal Disease on Chronic 
Hemodialysis  
 
 
 
Celerion Project No.: CA [ADDRESS_1089417] No.: 3G3-18-02 
 
 
US IND No.: 127850  
 
 
 
 
 
 
 
GCP Statement  
This study is to be performed in full compliance with the protocol, Good Clinical Practices 
(GCP), and applicable regulatory requirements. All required study documentation will be 
archived as required by [CONTACT_12721].  
 
Confidentiality Statement  
This document is confidential. It contains proprietary information of Aron ora, Inc.  and/or  
Celerion . Any viewing or disclosure of such information that is not authorized in writing by 
[CONTACT_214078], Inc.  and/or  Celerion  is strictly prohibited. Such information may be used solely for 
the purpose of reviewing or performing this study.  
 
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment 1 14June 2018 
 
Page 2 1 PROTOCOL REVISION HISTORY  
Date/Name  [CONTACT_62578]  
14June2018  
by [CONTACT_790452] , Amendment [ADDRESS_1089418], this protocol 
is being amended to provide justification  for the use of a 
placebo -control design . In addition, in formation on safety 
measures that will be undertaken by [CONTACT_790453] . 
Thus , Section 8.4.1 Rationale for this Study and Study Design , 
Section  8.5 Risks and/or Benefits to Patients , and 
Section  11.3 Early Termination of Patients from the Study were 
updated . Section  13.3 Hemo dialysis Procedure and Blood Clots in 
the Dialyzer Cartridge was created . 
In addition, the following changes were made:  
- Section 11.2 Exclusion criteria, criterion 2 was updated 
(changes in  strikethrough and additions in bold) : “With the 
exception of unfrac tionated heparin during HD, 
Cconcomitant or prior use of anticoagulant/antiplatelet agents 
(e.g., low molecular weight heparins,  warfarin, api[INVESTIGATOR_3822], 
bivalirudin, ticagrelor, edoxaban, dabigatran, rivaroxaban, 
clopi[INVESTIGATOR_7745], prasugrel, ticlopi[INVESTIGATOR_5325], eptifibati de, tirofiban, 
dipyridamole, diclofenac , and all other  NSAIDs) that may 
affect hemostasis for 2 weeks prior to check -in on Day -8 and 
throughout the study. ” 
- Section 11.2 Exclusion criteria, criterion 3 was updated 
(changes in  strikethrough and additions in  bold) : “Use of 
unfractionated heparin for HD sessions  from check -in on 
Day -8 and throughout the study. ” 
- Section 11.2 Exclusion criteria, criterion 9: The value for 
hemoglobin concentration at screening was increased from 
8.5 g/dL to 10  g/dL . The hemoglobin limit was increased to 
allow for the possibility of blood loss of up to 228 mL i f there 
is a clot in the dialyzer circuit.  Also,  the 5 other clinical 
laboratory values had no specific timing  on when these values 
were required; thus , “at screenin g” was added for these clinical 
laboratory tests.  
- Section 13.6 Dialysate Analysis; this section was added as 
sample s of the dialysate will be taken for future analysis (e.g., 
assessment of urea or drug level in the dialysate). Samples will 
be stored for up  to 5 years).  
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment 1 14June 2018 
 
Page 3 - Section 13.7.1 Blood Sampling and Processing , wording was 
added that leftover samples would be stored for up to 5 years.  
Updates in blood volume (i.e., correction in number of samples 
were made increasing the total blood volume by [CONTACT_2902] 5 mL (from 
430 mL to 435.9  mL) 
Minor editorial , consistency, and  formatting updates were made 
throughout the protocol.  
25May 2018  
by [CONTACT_790454]23900 (3G3 -18-02), Final Protocol Amendment 1 14June 2018 
 
Page 4 2 PRINCIPAL INVESTIGATOR [INVESTIGATOR_78411] – SIGNATORIES  
A Phase 2, Randomized, Double -Blind, Placebo -Controlled Study of the Safety and 
Efficacy/Potency of a Single Dose of Xisomab 3G3 , Administered at the Beginning of a 
Regular Hemodialysis Procedure , in Patients with End -Stage Renal Disease on Chronic 
Hemodialysis  
 
SPONSOR:  Aronora, Inc.  
[ADDRESS_1089419], Ste 200A  
Portland, Oregon [ZIP_CODE], [LOCATION_003]  
Tel.: [PHONE_4552] -0250  
 
SPONSOR’S 
REPRESENTATIVE:   
Christina Lorentz, PhD  
Senior Scientist  
Tel.: [PHONE_4552] -0250  
E-mail: [EMAIL_5912]   
   
 Signature   [CONTACT_121313] S AND CLINICAL SITE S: 
  
 
  
 Signature  
[INVESTIGATOR_67476]:   Date  
 
  
 Signature  
[INVESTIGATOR_67476]:   Date  
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment [ADDRESS_1089420], Ste 200A  
Portland, Oregon [ZIP_CODE], [LOCATION_003]  
Tel.: [PHONE_4554] -6842  
Fax: [PHONE_4556] -7330  
Mobile: [PHONE_4555] -1213  
E-mail: [EMAIL_4159]  
 
Protocol Author  Natacha Benrimoh, M.Sc.  
Associate Director  
Celerion  
[ADDRESS_1089421]  
Montreal, Quebec H4M 2N8 , Canada  
Tel.: [PHONE_4557] -8742  
Fax: [PHONE_4557] -8700  
E-mail: natacha.benrimoh @celerion.com  
 
Pharmacokinetic and Statistical Analyses  
 Celerion  
[ADDRESS_1089422]  
Montreal, Quebec H4M 2N8 , Canada  
Tel.: [PHONE_4557] -9090  
Fax: [PHONE_4557] -8700  
 
and/or  
 
Celerion  
[ADDRESS_1089423], Nebraska [ZIP_CODE] , [LOCATION_003]  
Tel.: [PHONE_4558] -2811  
Fax: +[PHONE_15840]  
 
 
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment 1 14June 2018 
 
Page 6 4 TABLE OF CONTENTS  
1 PROTOCOL REVISION HISTORY  ................................ ................................ .............  2 
2 PRINCIPAL INVESTIGATOR [INVESTIGATOR_78411] – SIGNATORIES  .........................  4 
3 ADDITIONAL KEY CONTACTS FOR THE STUDY  ................................ ................  5 
4 TABLE OF CONTENTS  ................................ ................................ ................................ . 6 
5 SYNOPSIS  ................................ ................................ ................................ .........................  9 
6 STUDY EVENTS FLOW CHART  ................................ ................................ ...............  12 
7 ABBREVIATIONS  ................................ ................................ ................................ .........  16 
8 INTRODUCTION ................................ ................................ ................................ ...........  19 
8.1 Background  ................................ ................................ ................................ .............  19 
8.2 Nonclinical Studies  ................................ ................................ ................................ . 20 
8.2.1  Pharmacology  ................................ ................................ ...........................  20 
8.2.2  Pharmacokinetics  ................................ ................................ ......................  20 
8.2.3  Toxicology  ................................ ................................ ................................  21 
8.3 Clinical Studies  ................................ ................................ ................................ ....... 21 
8.3.1  Safety Data  ................................ ................................ ................................  22 
8.3.2  Pharmacokinetics and Pharmacodynamics Data  ................................ ...... 22 
8.4 Rationale  ................................ ................................ ................................ ..................  25 
8.4.1  Ration ale for this Study and Study Design  ................................ ...............  25 
8.4.2  Rationale for the Dose Selection  ................................ ...............................  26 
8.5 Risks and/or Benefits to Patients  ................................ ................................ .............  27 
9 OBJECTIVES AND ENDPOINTS  ................................ ................................ ...............  28 
9.1 Objectives  ................................ ................................ ................................ ................  28 
9.2 Endpoints  ................................ ................................ ................................ .................  28 
10 STUDY DESIGN  ................................ ................................ ................................ .............  29 
10.1 Overall Study Design and Plan  ................................ ................................ ...............  29 
10.1.1  Confinement and Follow -Up ................................ ................................ .... 30 
10.1.2  End of Study Definition  ................................ ................................ ............  30 
11 STUDY POPULATION  ................................ ................................ ................................ . 31 
11.1 Inclusion Criteria  ................................ ................................ ................................ ..... 31 
11.2 Exclusion Criteria  ................................ ................................ ................................ .... 32 
11.3 Early Termination of Patients from the Study  ................................ ........................  34 
11.4 Study Restrictions  ................................ ................................ ................................ ... 35 
11.4.1  Prohibitions and Concomitant Medication  ................................ ...............  35 
11.4.2  Meals  ................................ ................................ ................................ .........  35 
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment 1 14June 2018 
 
Page 7 11.4.3  Activity  ................................ ................................ ................................ ..... 35 
12 TREATMENTS ................................ ................................ ................................ ...............  36 
12.1 Treatments Administered  ................................ ................................ ........................  36 
12.2 Dose Modification  ................................ ................................ ................................ ... 36 
12.3 Method of Assigning Patients to Treatment Groups  ................................ ...............  37 
12.4 Blinding  ................................ ................................ ................................ ...................  37 
12.4.1  Maintenance of Randomization  ................................ ................................  37 
12.4.2  Procedures for Breaking the Blind Prior to Study Completion  ................  37 
12.4.3  Revealing of Randomization ................................ ................................ ..... 38 
12.5 Treatment Compliance  ................................ ................................ ............................  38 
13 STUDY ASSESSMENTS AND PROCEDURES  ................................ .........................  39 
13.1 Screening  ................................ ................................ ................................ .................  39 
13.2 Safety an d Tolerability Assessments  ................................ ................................ ....... 39 
13.2.1  Physical Examination ................................ ................................ ................  39 
13.2.2  Vital Signs  ................................ ................................ ................................ . 40 
13.2.3  ECG Monitoring  ................................ ................................ .......................  40 
13.2.4  Body Weight  ................................ ................................ .............................  40 
13.2.5  Vascular Access Site Reaction Assessment  ................................ ..............  40 
13.2.6  Bleeding of Access Site  ................................ ................................ ............  41 
13.2.7  Clinical Laboratory Tests  ................................ ................................ ..........  42 
13.2.8  Adverse Events  ................................ ................................ .........................  43 
[IP_ADDRESS]  Adverse Event Definition  ................................ .........................  43 
[IP_ADDRESS]  Monitoring  ................................ ................................ ...............  43 
[IP_ADDRESS]  Reporti ng ................................ ................................ ..................  43 
[IP_ADDRESS]  Serious Adverse Event  ................................ .............................  45 
13.3 Hemodialysis Procedure and Blood Clots in the Dialyzer Cartridge  ......................  45 
13.4 Immunogenicity Assessment  ................................ ................................ ...................  46 
13.5 Pharmacodynamic Assessments  ................................ ................................ ..............  46 
13.6 Dialysate Analysis  ................................ ................................ ................................ ... 47 
13.7 Pharmacokinetic Assessments  ................................ ................................ .................  47 
13.7.1  Blood Sampling and Processing  ................................ ...............................  47 
13.7.2  Plasma Pharmacokinetic Parameters  ................................ ........................  47 
13.7.3  Analytical Method  ................................ ................................ ....................  48 
13.8 Blood Volume Drawn for Study Assessments  ................................ ........................  49 
14 STATISTICAL CONSIDERATIONS  ................................ ................................ ..........  50 
14.1 Sample Size Determination  ................................ ................................ .....................  50 
14.2 Population for Analyses  ................................ ................................ ..........................  50 
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment [ADDRESS_1089424] Access to Source Data/Documents  ................................ ..............................  [ADDRESS_1089425] OF FIGURES  
Figure 1:  Mean Concentration Profile  ................................ ................................ ...........  23 
Figure 2:  Mean aPTT Profile Over Time  ................................ ................................ ...... [ADDRESS_1089426] OF TABLES  
Table 1:  Key PK Parameters  ................................ ................................ ........................  23 
Table 2:  Cohort and Treatment Randomization  ................................ ...........................  29 
Table 3:  Identity of Investigational Products  ................................ ...............................  36 
Table 4:  Blood Volume during the Study  ................................ ................................ .... 49 
 
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment 1 14June 2018 
 
Page 9 5 SYNOPSIS  
Compound:  xisomab 3G3 (anti -factor [F] XI monoclonal antibody, IgG4)  
Active ingredient : xisomab 3G3 ( ∼15 mg/mL)  
Excipi[INVESTIGATOR_840]: 8% sucrose, 10 mM histidine, 30 mM arginine HCl,  
10 mM methionine, 80 ppm polysorbate 80  
Clinical Indication:  Prevention or treatment of thrombotic and thromboembolic 
diseases  
Study Phase:  Phase 2 
Study Objective s: The primary objective of this study is : 
• To assess the safety and tolerability of a single dose of 
xisomab  3G3 when injected  through a port into the proximal 
(arterial) dialysis line immediately after initiation of a 
hemodialysis ( HD) procedure in patients  with end stage renal 
disease ( ESRD ). 
The s econdary objectives of this study are:  
• To assess the pharmacodynamics ( PD) of a single dose of 
xisomab 3G3 when injected  through a port into the proximal 
(arterial) dialysis line immediately after initiation of a HD 
procedure in patients  with ESRD . 
• To asse ss the efficacy of a single dose of xisomab 3G3 on HD 
efficiency when injected  through a port into the proximal 
(arterial) dialysis line immediately after initiation of a HD 
procedure in patients  with ESRD . 
• To assess the pharmacokinetic s (PK) of a single dose of 
xisomab 3G3 when injected  through a port into the proximal 
(arterial) dialysis line immediately after initiation of a HD 
procedure in patients  with ESRD . 
Summary of Study 
Design:  This is a phase 2, randomized, double -blind, placebo -controlled, 
single -dose study of xisomab  3G3 designed to evaluate the safety, 
efficacy /potency , and PK at [ADDRESS_1089427] undergoing HD.  
Patient s will be enrolled into Cohort 1 or Cohort 2; cohorts will be 
dosed sequentially. Within a cohort, patients  will be randomized to 
active drug or placebo  as summarized below : 
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment 1 14June 2018 
 
Page 10 Cohort  Treatment  Active:Placebo  Cohort Size  
1 Infusion dose of 0.25 mg/kg 
xisomab 3G3 or placebo  2:1 9-12 
2 Infusion dose of 0.5 mg/kg 
xisomab 3G3 or placebo  2:1 9-12 
This study includes a screening period of 28 days  prior to 
checking -in to the clinical research unit on Day  -8.  From Day  -7 
(one week prior to dosing on Day 1)  through Day  -1, all patients  
will undergo HD  3 times and will be assessed for all scheduled 
procedures  and endpoints before and after each HD session  as per 
the Study Events Flow Chart (Section  6).  
On Study Day 1, prior to dosing, patients  will undergo baseline 
measurements followed by [CONTACT_214075] a regular HD procedure, 
consistently using only one type of dialyzer cartridge in eac h 
patients . Immediately after the start of blood perfusion, a single 
dose of xisomab  3G3 or matching placebo will be injected through 
a port into the flowing arterial blood in the proximal dialysis line . 
Patients  will continue to  undergo HD procedures and scheduled 
assessments from Day 1 through  Day 12.   
Study assessments will include physical examinations, vital signs, 
electrocardiogram (ECGs) , clinical laboratory tests, HD vascular 
access site (AV fistula or AV graft)  reaction, antibody titer 
(immunogenicity), adverse events (AE s), PD blood sampling 
(coagulation parameters) , and PK blood sampling to be performed 
throughout the study according to the Study Events Flow Chart 
(Section  6). On Days  -7, -5, and -3 and Days 1,  3, 5, and 12, 
bleeding time from the HD vascular  access site s on the AV fistula  
or AV graft  (ladder or butto nhole technique) will be evaluated at 
the end of the HD session . The dialyzer cartridge will be rinsed and 
visually inspected at the end of the HD procedure and graded 
against a standardized visual assessment scale. After visual 
assessment, t he used and ri nsed dialyzer cartridge will be frozen 
and saved for later retained content (deposited blood -derived 
material) analysis. The number of dialyzer cartridges used for the 
HD session will be recorded.  
All patients  who received the study drug  or placebo  (including 
patient s who terminate the study early) will undergo follow -up 
procedures at the Clinical Research Unit ( CRU ) approximately 
12 days after dosing . 
Number of Patient s: A total of up to 24 adult male and female patients  will be enrolle d; 
9-[ADDRESS_1089428] 50% of 
females and at least 30% of a race/ethnicity minority group.  An 
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment 1 14June 2018 
 
Page 11 attempt will also be made to approximately match key 
characteristics , including sex, average age, and weight per cohort.  
Dosage, Dosage 
Form, Route, and 
Dose Regimen:  On Day 1, patients  in each cohort will receive a single dose of 
xisomab 3G3 or placebo injection into the proximal (arterial) 
dialysis line on one occasion.  Cohort  1 will be conducted prior to 
initiation of Cohort 2.  
Planned doses will be as follows:  
Cohort 1: 0. 25 mg/kg xisomab 3G3 or matching placebo  
Cohort 2: 0.5 mg/kg xisomab 3G3 or matching place bo 
Key Assessments : Safety  
Safety assessment will include  physical examinations, vital signs, 
ECGs, clinical laboratory tests , vascular access  site reaction, 
bleeding time, and AEs.   
Number/severity of AE will be tabulated and summary statistics for 
the 12 -lead ECGs, vital signs, and clinical laboratory tests may be 
computed and provided, as deemed clinically appropriate.   
Pharmacodynamics:  
Efficacy/potency assessment will be measured as efficiency of the 
hemodialysis by [CONTACT_790455] (ranked by 
[CONTACT_31519])  in the dialyzer cartridge , protein accumulation in 
the HD filter, BUN  and potassium blood levels , length of HD, 
measurement of urea removed by 3 hours of dialysis , and total 
dialysate urea ( Kt/V and urea reduc tion ratio [URR )]. Coagulation 
tests will also be performed . 
Change from baseline will be summarized by [CONTACT_3148] (2  active 
dose levels and pooled placebo) and per timepoints using 
descriptive statistics.  
Pharmacokinetics:  
The following PK parameters will be calculated for xisomab 3G3  in 
plasma , as appropriate : AUC0 -t, AUC0 -inf, AUC%extrap, Cmax, 
Tmax , Kel, t½, CL, and Vss. 
PK parameters will be summarized by [CONTACT_790456].  
Immunogen icity:  
Development of antibodies against the study drug will be evaluated 
by [CONTACT_231273] -drug antibody (ADA) titer . 
 
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment 1 14June  2018 
 
Page 12 6 STUDY EVENTS FLOW CHART  
Study Procedures  a: 
Screening b: 
(Day -37 to 
Day -9) Study Days  
Evaluation Period  
Days → -8 -7 -6 -5 -4 -3 
HD →  HD d:  HD d:  HD d: 
Hours →  C-I c: start  end  start  end  start  end 
Administrative Procedures            
Informed Consent  X          
Inclusion /Exclusion Criteria  X X         
Medical History  X          
Safety Evaluations             
Full Physical Examination e: X X         
Height  X          
Weight  X X X f: X g: X X f: X g: X X f: X g: 
12-Lead Safety ECG  X X         
Vital Signs ( HR, BP, RR, and T)  X X X f:   X f:   X f:  
Bleeding of Access Site     X g:    X g:   X g: 
Hem, Serum Chem  h:, and U A i: X X         
Coagulation j:  X  X f: X g:  X f: X g:  X f: X g: 
Platelet Count s:   X f: X g:  X f: X g:  X f: X g: 
Serum Pregnancy Test ( ♀only)  X X         
Serum FSH ( PMP  ♀only)  X          
Urine /Saliva  Drug and Alcohol Screen  X X         
HIV/Hepatitis Screen  X          
AE Monitoring   X 
ConMed s Monitoring  X X 
Other Procedures            
Blood BUN and Potassium  (for Kt/V and 
URR)  s:   X f: X g:  X f: X g:  X f: X g: 
Dialysate Analysis   X k: X k:  X k: X k:    
Visual Assessment and Processing of 
Dialyzer Membrane     X l:   X l:   X l: 
Confinement in the CRU   X 
Visit  X          
 
 
 
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment 1 14June  2018 
 
Page 13  
 
Study Procedures  a: Study Days  
PK/PD Period  
Days → 1 2 3 4 5 6 
HD → HD d:   HD d:   HD d:  
Hours →  0-0.016  0.167  0.5 1 2 3 4 6 8 12 16 24 48 start  end 72 96 start  end 120 
Safety Evaluations                       
Abbreviated Physical 
Examination e: X m:                   X p: 
Weight  X f:     X g:      X  X f: X g: X  X f: X g: X p: 
12-Lead Safety ECG  X m:                   X p: 
Vital Signs (HR, BP, RR and T)  X m:   X           X f:    X f:  X p: 
Bleeding of Access Site       X g:         X g:    X g:  
Hem, Serum Chem h:, and UA i: X m:                   X p: 
Coagulation j: X f:     X g:        X f: X g:   X f: X g: X p: 
Platelet Count s: X f:     X g:        X f: X g:   X f: X g:  
AE Monitoring  X 
ConMed s Monitoring  X 
Study Drug Administration / 
PK/PD/Immunogenicity                      
Xisomab 3G3 Administration n: X                    
Blood for free xisomab 3G3 PK  X o: X X X X X X X X X X X X o:    X o:   X p: 
Blood for free xisomab 3G3 P D 
(aPTT) s: X o: X X X X X X X X X X X X o:    X o:   X p: 
Blood for Immunogenicity  X m:                    
Blood BUN and Potassium  (for 
Kt/V and URR) s: X f:     X g:        X f: X g:   X f: X g:  
Dialysate Analysis    X k:   X k:        X k: X k:      
Visual Assessment and 
Processing of Dialyzer 
Membrane   
    X l:         X l:    X l:  
Other Procedures                      
Vascular Access Site Reaction  X m:     X q:         X q:    X q:  
Confinement in the CRU  X 
Return Visit                      
 
  
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment 1 14June  2018 
 
Page 14 Study Procedures  a: Study Days 
Follow -up Period  
Days → 7 8 9 10 11 12 
HD →  HD d:  HD d:  HD d:  
Hours →   start  end  start  end  start  end  
Safety Evaluations             
Abbreviated Physical Examination  e:          X r: 
Weight   X f: X g:  X f: X g:  X f: X g:  
12-Lead Safety ECG           X r: 
Vital Signs ( HR, BP, RR, and T )   X f:   X f:   X f:  X r: 
Bleeding of Access Site          X g:  
Hem, Serum Chem  h:, and U A i:          X r: 
Coagulation  j:        X f: X g: X r: 
Platelet Count s:        X f: X g:  
Serum Pregnancy Test ( ♀only)           X r: 
AE Monitoring  X X 
ConMed s Monitoring  X  
Study Drug Administration / 
PK/PD/Immunogenicity            
Blood for free xisomab 3G3 PK           X r: 
Blood for free xisomab 3G3 P D (aPTT) s:  X o:   X o:      
Blood for Immunogenicity           X r: 
Other Procedures            
Blood BUN  and Potassium  (for Kt/V and URR)         X f: X g:  
Dialysate Analysis         X k: X k:  
Visual Assessment and Processing of Dialyzer 
Membrane          X l:  
Return Visit s  X  X  X 
 
  
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment 1 14June  2018 
 
Page 15 a: For details on Procedures, refer to Section  13 
b: Within 28 days  prior to Day -8. 
c: Patients  will be admitted to the CRU on Day -8, at the time indicated by [CONTACT_790457] 6 or prior early termination . 
d: Patients  will undergo hemodialysis [ADDRESS_1089429] schedule  which will be the same throughout the study . 
e: Symptom -driven physical examination may be performed  at other times , at the PI’s or designee ’s discretio n. 
f: To be performed ~  1 hour prior to the start of hemodialysis . 
g: To be performed at the end of hemodialysis .  
h: Samples for serum chemistry will be obtained following a fast of at least [ADDRESS_1089430] fasted 
for 4 hours prior to the serum chemistry sample is taken.  
i: For anuric patients , urinalysis may  not be performed .  
j: Coagulation parameters  (activated partial thromboplastin time  [aPTT ], prothrombin time [PT], and international normalized ratio [ INR]). 
k: The dialysate sample will be taken at 30 min utes and at  3 hours after the start of hemodialysis . The dialysate will be freeze  and sent to  Aron ora. 
l: To be performed when the dialyzer cartridge is removed and collected at the end of HD.  
m: To be performed prior to dosing.  
n: A single dose of xisomab 3G3 or matching placebo will be administered at Hour 0. The dose will be injected through a port int o the flowing arterial 
blood in the proximal dialysis line according to the randomization schedule, immediately after the start of HD. 
o: When the PK  or PD  sample is on an HD day, the sample should be taken at least 1 hour prior the start of HD session. The actual time will be rec orded.  
p: To be performed at discharge or early termination ; the PK and aPTT should be taken at 120 hour postdose . 
q: The vascular acces s sites ( AV fistula or AV graft puncture sites) are to be evaluated immediately after the end of HD and removal of the needles from 
the fistula or graft for bleeding cessation or other reactions.  
r: All patients who received the study drug or placebo (includi ng patients  who terminate the study early) will undergo follow -up procedures at the Clinical 
Research Unit (CRU) approximately [ADDRESS_1089431] HD . Events performed on Day 12  can performed at end of HD if 
more appropriate . 
s: Platelet count, BUN and potassium, and aPTT value will be taken from the hematology, serum chemistry, and coagulation sample,  respectively, when 
these are scheduled to be collected at the same time. Samples will not be taken twice at a same timepoint.  
Abbreviations: ♀ = Females, AE  = Adverse events, BUN  = Blood urea nitrogen, BP = Blood pressure, C -I = Check -in, Chem  = Chemistry, 
ConMeds  = Concomitant medication, CRU  = Clinical research unit, ECG  = Electrocardiogram, FSH  = Follicle -stimulating hormone, FU  = Follow -up, 
Hem  = Hematology, HD = Hemodialysis, HIV = Human immunodeficiency virus, HR  = Heart rate, Kt/V  = ratio of volume of fluid completely cleared of urea  
PD = Pharmacodynamic, PK  = Pharmacokinetics, PMP  = Postmenopausal, RR  = Respi[INVESTIGATOR_13521] y rate, T  = Temperature, UA  = Urinalysis  URR  = Urea reduction 
ratio. 
 
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment [ADDRESS_1089432]  Aspartate aminotransferase   
AUC%extrap  Percent of AUC0 -inf extrapolated   
AUC0 -t Area under the concentration -time curve, from time  [ADDRESS_1089433] observed 
non-zero concentration  (t)  
AUC0 -inf Area under the concentration -time curve, from time  0 extrapolated to 
infinity   
bpm Beats per minute   
BMI  Body mass index   
°C Degrees Celsius   
CFR  Code of Federal Regulations   
CI Confidence interval   
CL Apparent total plasma clearance after oral (extravascular) administration   
Cm Centimeter   
Cmax  Maximum observed concentration   
CRF  Case report form   
CRU  Clinical Research Unit   
CS Clinical significant   
CV Coefficient of variation   
ECG  Electrocardiogram   
ESRD  End stage renal disease   
FDA  Food and Drug Administration   
FIH First in Human   
FSH Follicle -stimulating hormone   
FXI Factor  XI  
FXIa Activated FXI   
FXII  Factor  XII  
FXIIa  Activated FXII   
G Gram   
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment 1 14June  2018 
 
Page 17 GCP  Good Clinical Practice   
GLP  Good Laboratory Practice   
h Hour   
HBsAg  Hepatitis B surface antigen   
hCG  Human chorionic gonadotropin   
HCV  Hepatitis C virus   
HD Hemodialysis   
HIV Human immunodeficiency virus   
IB Investigator’s Brochure   
ICF Informed Consent Form   
ICH International Council on Harmonisation   
IL Interleukin   
IND Investigational New Drug   
INR International normalized ratio   
IRB Institutional Review Board   
IV Intravenous   
Kel Apparent terminal elimination rate constant   
Kg Kilogram   
L Liter   
LS Least squares   
m2 Meters squared   
MedDRA® Medical Dictionary for Regulatory Activities®  
mg Milligram   
mL Milliliter   
mmHg  Millimeter of mercury   
MRT  Mean residence team   
msec Millisecond   
N Sample size   
No. Number   
PBMC  Peripheral blood mononuclear cells   
PD Pharmacodynamics   
PI [INVESTIGATOR_790444]23900 (3G3 -18-02), Final Protocol Amendment 1 14June  2018 
 
Page 18 PK Pharmacokinetic(s)   
PT Prothrombin time   
QA Quality Assurance   
QTc Corrected value of the interval between the Q and T waves on the 
electrocardiogram tracing   
SAE  Serious adverse event   
SAP Statistical analysis plan   
TEAE  Treatment emergent adverse event   
Tmax  Time to reach maximum observed concentration   
t½ Apparent terminal elimination half -life  
URR  Urea reduction ratio   
US [LOCATION_002]   
[LOCATION_003]  [LOCATION_002] of America   
Vz Apparent volume of distribution during the terminal elimination phase 
after oral (extravascular) administration   
WHO  World Health Organization   
 
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment 1 14June  2018 
 
Page 19 8 INTRODUCTION  
This study  will be conducted in compliance with the protocol, Good Clinical Practice (GCP), 
and applicable regulatory requirements. The study  population will be comprised of adult 
male and/or female patients with end stage renal disease . 
A brief overview of available information regarding xisomab 3G3 follows below. Details can 
be found in the xisomab 3G3 Investigator’s Brochure ( IB 2018 ). 
8.[ADDRESS_1089434] (intrinsic) pathway of coagulation and is 
intended to address the problem of dose limiting bleeding side effects of current 
antithrombotic agents. Xisomab 3G3 was developed by [CONTACT_214078], Inc. and the current 
form ulation is intended for IV administration. The proposed indications for xisomab 3G3 
include prevention or treatment of thrombotic and thromboembolic diseases, such as venous 
thrombosis and thromboembolism.  
Aronora, Inc. has conducted a comprehensive noncli nical pharmacology and toxicology 
program in support of clinical development of xisomab 3G3. Experimental evidence suggests 
that contact [CONTACT_300213], but it has no known role in normal 
hemostasis. Contact [CONTACT_790458] -activation of coagulation 
factor  (F) XII on negatively charged surfaces. Activated FXII (FXIIa) then activat es FXI and 
ultimately leads to generation of the procoagulant enzyme thrombin from prothrombin. The 
therapeutic monoclonal antibody xisomab 3G3 binds the apple 2 domain of FXI and 
interferes with the activation of FXI by [CONTACT_300215]. Importantly, this interaction selectively 
prevents activation of FXI by [CONTACT_790459], or other mechanisms, nor 
does it interfere with the catalytic activity of activated FXI (FXIa) on its hemostatic 
substrates , including FIX . Because FXIIa does not contribute to the hemostasis of 
mammalian species, an d activation of FXI by [CONTACT_300217] a pathological event that appears to 
promote thrombosis in experimental animals, inhibition of FXI activation by [CONTACT_790460] 3G3 is expected to be a safe and effective antithrombotic intervention in humans 
who are at  risk of or have developed thrombosis.  
The goal of xisomab 3G3 treatment is to achieve safe anticoagulation for several days with a 
single dose. A single dose of xisomab 3G3 demonstrated potent and sustained antithrombotic 
effects in both mice and nonhuman  primate models, and showed no toxicity at and above 
saturating doses in nonclinical Good laboratory Practice (GLP) toxicity studies in rats and 
cynomolgus monkeys. Saturation of binding to the molecular target and the maximum FXI 
inhibitory effect is achi eved at a relatively low dose of xisomab 3G3 because FXI circulates 
at a low plasma concentration (3 to 10 mg/L), and the antibody has high affinity toward FXI.  
The effect of increasing the dose above the saturating level results in prolongation of 
anticoa gulation in a dose -dependent manner. Since there has been no observed toxicity 
associated with a dose more than 50 -fold over the predicted effective target dose in humans 
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment [ADDRESS_1089435] of coagulation by [CONTACT_300219] 3G3 or its murine precursor, 
xisomab 14E11, is antithrombotic as demonstrated by [CONTACT_790461] d in several experimental animal models of thrombosis, including a mouse 
model of FeCl3 -induced arterial thrombosis (Study No. AB023.4), a mouse model of sepsis 
(Study No. AB022.4), and a well -established model of thrombosis in baboons 
(Study  No. AB023.5).  Importantly, while treatment with xisomab 3G3 or 14E11 attenuated 
thrombosis in these experimental models of thrombosis, no demonstrable effect on 
hemostasis was observed. These data suggest that in contrast to  other antithrombotics,  
currently marketed or under development,  that target the functionality of coagulation cascade 
components downstream of FXII and important for both thrombosis and normal hemostasis, 
xisomab 3G3 is designed to  prevent or treat  thrombosis by [CONTACT_790462], thereby [CONTACT_790463] . 
8.2.2 Pharmacokinetics  
Pharmacokinetics were evaluated in a non -GLP study in baboons (Papio  Anubis) in which 
1 mg/kg of xisomab 3G3 was administered by [CONTACT_300221] 3G3 plasma 
concentration was measured over time. Non -compartmental analysis of the xisomab 3G3 
plasma concentration versus time curve revealed the maximal plasma con centrations 
normalized to dose (Cmax/Dose) was 19.66 ± 0.56 L/kg, the area under the concentration 
time curve from time [ADDRESS_1089436] time point measured postdose normalized to dose 
(AUC0 -xh/Dose) was 1594 ± 82 kg x h/L, and the apparent volume of distribu tion (Vd) was 
0.050 ± 0.0012 L/kg. Group mean terminal elimination half -lives ( t½) ranged from 45 to 
75 hours and the mean residence time (MRT) ranged from 88 to 110 hours in baboons after a 
1 mg/kg IV injection.  
In addition, toxicokinetics were evaluated  as part of the pi[INVESTIGATOR_300194]. In both studies, IV doses of 0, 2, 10, and 
50 mg/kg of xisomab 3G3 were administered by [CONTACT_300222]. All animals except 
controls showed systemic exposure to xisom ab 3G3 following single IV dose. IV infusions of 
xisomab 3G3 in cynomolgus monkeys resulted in peak free xisomab 3G3 plasma 
concentrations at the first or second time point evaluated, approximately 0.[ADDRESS_1089437] profiles. In the 
absence of the recovery data for the main study animals, the terminal elimination phase could 
only be estimated with confide nce for one male who received 10 mg/kg, with t½, CL and Vd  
of 31.9 hours, 0.513 mL/h/kg, and 23.6 mL/kg, respectively. Inclusion of the recovery  
animals (n = 2/sex/group) for all dose levels allowed for better characterization of the  
terminal elimination p hase, however, it could only be estimated for six out of twelve 
recovery animals. Consequently, individual t½ were longer and ranged from 61.4  to 
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment 1 14June  2018 
 
Page 21 248 hours. Individual CL and Vd were estimated between 0.142 and 0.535 mL/h/kg and 
34.0 and 57.8  mL/kg, respec tively. I ntravenous  infusions of xisomab 3G3 in rats resulted in 
peak xisomab 3G3 plasma concentrations at the first or second time point evaluated, 
approximately 0.5  - 3 hours following administration. The terminal elimination phase was 
only characterized  for the males and females at the 50 mg/kg dose level, as the terminal 
elimination phase for the 2  and 10 mg/kg dose levels was not reported due to either a 
coefficient of determination less than 0.800 or the extrapolation of the AUC to infinity 
represente d more than 20% of the total area. The t½ for the males and females at the 
50 mg/kg dose level was 155  hours and 185  hours , respectively. The average volume of 
distribution (Vd ) was 45.2  mL/kg and 45.3  mL/kg for the males and females , respectively 
and the clearance (CL) was 0.202  and 0 .170 mL/h/kg for the males and females , respectively.  
8.2.3 Toxicology  
The safety and toxicity profile of xisomab 3G3 was evaluated in two, GLP, single dose acute, 
toxicity studies in Sprague Dawley rats and cynomolgus monkeys. In both studies, a single 
dose of xisomab 3G3 was administered intravenously at doses of 0, 2, 10 and 50 mg/kg and 
animals were evaluated for 3 days (main group) and 28 days (recov ery group) after dosing. 
Xisomab 3G3 was well tolerated in both species and no xisomab 3G3 -related AEs were 
observed. An expected aPTT prolongation was observed in all groups dosed with xisomab 
3G3, and the duration of effect was dose dependent. In the cyn omolgus monkey study, there 
was no difference in aPTT prolongation between males and females. The prolonged aPTT 
was first tested and observed 30 minutes after dosing (the first time point evaluated) and 
persisted until 336  hours postdose (Day 15) at 2 mg/ kg and 672 hours postdose (Day 29) at 
10 and 50  mg/kg. Similarly, in the Sprague Dawley rats study, prolonged aPTT was first 
observed at 30  minutes postdose (the first time point evaluated) and was generally of similar 
magnitude across the dose groups and genders; the duration of the effect increased with 
increasing dose. The No Observe d Adverse Effect Levels for both studies was determined to 
be 50  mg/kg. In addition to the toxicity studies, a GLP tissue cross reactivity study was 
performed in a panel of h uman tissue to assess potential cross -reactivity of xisomab 3G3. No 
xisomab 3G3 -related staining was observed in any of the human tissue samples (36 tissue 
types from 3 normal healthy donors). Cytokine release assays performed in peripheral blood 
mononucle ar cells (PBMCs) from 10 healthy donors revealed that xisomab 3G3, presented in 
three different stimulation formats, did not stimulate the release of interleukin (IL) -2, IL -4, 
IL-6, IL -10, tumor necrosis factor alpha or interferon gamma from PBMCs of any o f the 
donors.  
8.[ADDRESS_1089438] -in-human (FIH) study (Study No. 3G3 -15-01 [Celerion Project No.: CA19214]) was 
completed in the United -States on January 16, 2018. This study was a single ascending dose 
study in healthy adult male and female subjects  with the purpose of  collect ing safety, 
tolerability, PK, and PD information in order to support further development of 
xisomab  3G3. Four  (4) cohorts of either 6 subjects (Cohort 1 [4 active and 2 placebo]) or 
5 subjects (Cohorts 2, 3, and 4 [4 active and 1 placebo]) were dosed. Subjects received a 
single IV infusion (less than 5 minutes) of 0.1  mg/kg (Cohort  1), 0.5  mg/kg (Cohort  2), 
2 mg/kg (Cohort  3), or 5 mg/kg (Cohort  4) xisomab 3G3 or placebo.  
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment 1 14June  2018 
 
Page 22 A total of 21 subjects entered the study, received the stu dy medication  or placebo , and 
completed the study per protocol . Below is a summary of the preliminary data from this FIH 
study  as of 07 of May 2018 . 
8.3.1 Safety Data  
There were no deaths or SAEs experienced in this study. No subjects were discontinued due 
to AE s. Overall, 10 (48%) of 21 subjects experienced a total of 20 TEAEs in this study, with 
7 (44%) of 16 subjects following active treatment and 3 (60%) of [ADDRESS_1089439] incidence of TEAEs by [CONTACT_790464], experienced by 3 (19%) active -treatment subjects and 1 (20%) placebo 
subject. The most common TEAE in this study was productive cough, considered unrelated 
or unlikely treatment related and experienced by 2 (13%) active treatment su bjects . All other 
TEAEs were experienced by [ADDRESS_1089440].  The majority of events (17) were mild (Grade 1) in 
severity and 3 were moderate (Grade 2).  Moderate events included increased diastolic BP 
(2 mg/kg xisomab 3G3 ), productive cough ( 5 mg/kg xisomab 3G3 ), and upp er respi[INVESTIGATOR_19629] (0.5 mg/kg xisomab 3G3 ). As expected, increases from baseline in aPTT were 
noted following all treatments, with greater magnitude and duration of these increases 
following administration of the higher dos es of xisomab 3G3.  
A single IV dose of xisomab 3G3  up to 5 mg/kg appeared to be safe and generally well 
tolerated by [CONTACT_214082].  
8.3.[ADDRESS_1089441] characterized at the 5 mg/kg dose level . The 
PK profiles and PK parameters in the 0.1 mg/kg dose level were not well characterized since 
the majority of concentrations fell below the LLOQ; thus, an insufficient number of  time 
points were available to char acterize the elimination phase from [ADDRESS_1089442] not been reliable at the doses below 5 mg/kg, noting 
that Vss appeared to be underestimated (were less than physiological blood volumes), and 
that half -life estimations increased when xisomab 3G3 was quantifiable for longer intervals.  
Plasma xisomab 3G3 exposure (AUCs and Cmax) increased with increasing dose levels. 
Although a dose proportionality analysis was not performed in this study, the mean PK 
param eter values indicated  that plasma xisomab 3G3 exposure appeared to increase in a 
slightly more than dose -proportional manner from 0. 5 to 5 mg/kg.  The PK parameters 
calculated from the 0.1  mg/kg dose were less robust as most parameters were estimated in 
only [ADDRESS_1089443] due to the absence of an observable elimination phase in 3 out of 4 subjects. 
The maximal concentrations peaked early, with Tmax values achieved before 1 hour 
following start of infusion. Elimination of the drug was decreased with increasing 
xisomab  3G3 doses, as shown by a lower  Kel, longer t½, and lower CL. A summary of mean 
PK parameters and mean concentration profile can be found in Table 1 and Figure 1. 
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment 1 14June  2018 
 
Page 23 Table 1: Key PK Parameters  
 Dose  
Parameters (units)  0.1 mg /kg  0.5 mg/kg  2 mg/kg  5 mg/kg  
N 3* 4 4 4 
AUC0 -t 
(ng•h/mL)  60.47 ± 38 368 500 ± 23 5 657 000 ± 24 28 270 000 ± 12 
AUC0 -inf 
(ng•h/mL)  - 370 400 ± 23 5 668 000 ± 24 28 290 000 ± 12 
Cmax  
(ng/mL)  124.9 ± 23 11 250 ± 9 42 750 ± 12 127 300 ± 3 
Tmax  
(h) 0.084 ± 2.4 1.15 ± 113  0.13 ± 65 1.01 ± 132 
t½ 
(h) - 16.638 ± 9 60.63 ± 7 121.49 ± 85 
CL 
(L/h) - 0.09 ± 20 0.026 ± 13 0.014 ± 23 
Vss 
(L) - 2.52 ± 24 3.72 ± 11 4.31 ± 18 
AUC = area under the concentration -time curve; CL = apparent body clearance; Cmax  = maximum observed plasma 
concentration; N = number of subjects; CV%  = coefficient variation ; t½= elimination half -life; Tmax = time of observed 
Cmax; V ss = apparent volume of distribution.  
Data presented as mean ± CV%  
* Non-zero c oncentration data from only 3 of 4 subjects was available for PK analysis.  
Figure 1: Mean Concentration Profile  
 

CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment [ADDRESS_1089444] was observed around the 0.5 mg/kg dose. Results showed that the maximum  
aPTT values  achieved  increased with increasing xisomab  3G3 dose levels , and the aPTT 
values decreased  towards baseline values  over time  as depi[INVESTIGATOR_6517] 2. The time for 
aPTT to return to baseline (±10%) increased as the dose levels increased. This may be 
correlated to a slower  in elimination rate of xisomab 3G3 from the plasma  as the doses 
increased.   
Figure 2: Mean aPTT Profile Over Time 
0 714 21 28 35 42 49 56 63 70 77 84 [IP_ADDRESS].61.82.02.2placebo
0.1 mg/kg
0.5 mg/kg
2 mg/kg
5 mg/kg
**
(3)**
(2)**(2)**
(1) (1)(1)
Time  Relative to Dosing (d)aPTT (fold change)
0 24 48 72 96 1201.[IP_ADDRESS].82.02.2
placebo
0.1 mg/kg
0.5 mg/kg
2 mg/kg
5 mg/kg
hoursaPTT (fold change)A
B
 
Legend:  
(A) aPTT of Cohorts 1 to 4 for the duration of the Phase 1 clinical trial to date in days (d)  
(B) aPTT data from the first 120 hours (h) post -dose.  
Numbers in parentheses indicate the number of subjects at that time point. *blood sa mple taken within 24  hours 
of time point indicated. **blood sample taken within 48  hours of time point indicated.  
 
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment 1 14June  2018 
 
Page 25 8.4 Rationale  
8.4.1 Rationale for this Study and Study Design  
A FIH study  was conducted in healthy subjects and concluded that a single dose of 
xisomab  3G3 up to 5 mg/kg was safe and generally well tolerated . Results also confirmed 
that x isomab 3G3 prolonged aPTT values; the magnitude and duration of which were 
dose-related . This study will explore the potential utility of single in fusion doses of xisomab 
3G3 in ESRD patients who are on chronic HD.  
Thromboembolic disease and bleeding are common comorbidities in subjects with chronic 
kidney diseases ( Lutz et al. , 2017 ). In most ESRD patients, heparin is routine ly used during 
outpatient HD to reduce clotting in the dialyzer cartridge and to improve HD efficiency. 
However, administration of heparin during HD temporally increases the risk of bleeding. A 
safe alternative for patients with active bleeding , or that ar e at a high risk for bleeding 
complications, is heparin -free dialysis ( Schwab et al ., 1987 ; Stamatiadis et al ., 2004 ; and 
Caruana et al ., 1987 ) and the majority of HD patients that are admitted to the hospi[INVESTIGATOR_790445].  
In this study design, subjects will be confined to the clinic for the majority of the trial and 
will not receive heparin d uring their HD sessions. While heparin -free HD can increase 
clotting within the dialyzer, resulting in the need for exchange of the dialyzer cartridge 
during HD in 5 -7% of the procedures ( Cronin and Reilly , 2010 ), there is no evid ence that HD 
without heparin results in increased thromboembolic complications. Indeed, heparin 
anticoagulation during HD is not intended for systemic thromboprophylaxis and a recent 
retrospective analysis of data from the [LOCATION_002] Renal Data System a nd electronic 
medical records shows that heparin -free HD is not associated with increased risk of 
thromboembolic events in ESRD patients ( Shen et al., 2013 ). Therefore, the removal of 
standard of care heparin anticoagulation  in eith er arm for the short duration of the study is 
not expected to place the patients at an increased risk for development of thromboembolic 
complications , and additionally enables the most rigorous assessment of safety and efficacy 
for xisomab 3G3 that would n ot be possible if heparin treatment was maintained.  
Xisomab 3G3 is expected to prevent pathologic thrombogenesis by [CONTACT_790465], or other mechanisms. As both 
thromboembolism and bleeding are common comorbidities in ESRD patients, safe 
anticoagulation is currently an unmet need for this patient population. Xisomab 3G3 is a 
fundamentally novel anticoagulant that is e xpected to reduce clot formation in vascular 
devices, including the hemodialyzer apparatus, without the increased risk of bleeding 
associated with heparin. In addition, data to date suggest that xisomab 3G3 may also reduce 
the incidence and severity of thr omboembolic events in these patients. Further, non -clinical 
data suggest that xisomab 3G3 reduces systemic inflammatory responses, which may be 
detrimental, and has been associated with contact [CONTACT_790466] g external organ support. As such, xisomab 3G3 stands as a promising 
alternative to other anticoagulants in this population. It is therefore of interest to assess 
xisomab 3G3 safety and effectiveness in ESRD patients on chronic HD.  
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment 1 14June  2018 
 
Page 26 A placebo arm is include d in this study design in order to robustly demonstrate the safety and 
efficacy of xisomab 3G3 while not placing the subjects at unnecessary risk, as mentioned 
above. The primary endpoint in this study is safety, measured as the number of adverse 
events th at occur during the observation period.  A heparin free inpatient HD observation 
period (Study Days -7 to 1) is included in the trial design to establish a baseline for the 
heparin -free procedure. Continuation of the heparin -free HD procedure during the 
subsequent trial period and i nclusion of a placebo arm allows for the determination of 
whether an adverse event is drug -related or not and permits accurate assessment of the safety 
of the study drug. The addition of a placebo arm also removes potential bias from the 
interpretation of AEs by [CONTACT_790467]. The secondary endpoint for this study is 
efficacy of xisomab 3G3 on hemodialysis efficiency which may be more clearly observed 
with a placebo control instead of an active control (e.g., heparin). While the placebo arm may 
be at the same  risk of clotting within the dialysis circuit  as during the pre -dosing period 
(Study Days -7 to 1) , data cited above suggests that these patients will not be at higher risk 
for either thromboembolic or bleeding compl ications. Should clotting  occur within the 
dialyzer cartridge  during a hemodialysis session  that results in dialyzer failure , the dialyzer 
cartridge will be replaced, and the patient will be closely monitored by [CONTACT_978]. It is important 
to note that replace ment of the dialyzer cartridge during HD is safe for the patient and a 
routine procedure in case s of dialyzer failure.  
8.4.2 Rationale for the Dose Selection   
Doses of 0.25 mg/kg and 0.5 mg/kg were selected for this phase 2 study  in order to provide 
adequate PD  and PK characterization but still allowing a safety margin should the results 
differ in this population compared to healthy subjects . The 0.25 mg/kg xisomab 3G3 dose is 
2.5-fold higher than the lowest dose in the FIH study. The 0.1 mg/kg dose in the FIH study 
had a short and modest, yet detectable PD effect  (several seconds of temporal aPTT 
prolongation). The 0.25 mg/kg dose is expected to provide an initial plasma concentration 
that is within the range of average FXI concent ration, the molecular target of xisomab 3G3, 
in human subjects , and may approach saturation in some individuals after full distribution. 
Therefore, it has the potential to exert brief pharmacological (anti -inflammatory , 
antithrombotic ) activity, possibly l asting up to a day, until elimination of the antibody and 
hepatic FXI secretion  that neutralizes  the antibody.  
The 0. 5 mg/kg dose was safely administered in the FIH study and allowed adequate 
characterization of the PK profile  in healthy adults . In additio n, following a 0.5 mg/kg a 
prolongation of aPTT was seen, with highest values measured at [ADDRESS_1089445] 72 hours postdose.  The 0.5 mg/kg xisomab 3G3 dose is 
expected to provide, after complete distribution, a plasma concentration that is approximately 
twice the average human plasma concentration of the FXI antigen. Therefore, this dose is 
expected to be overcome by [CONTACT_790468], and have pharmacological activity that 
lasts longer  than the lower dose lev el. 
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment 1 14June  2018 
 
Page 27 8.5 Risks and/or Benefits to Patients  
ESRD patients are often ill, and are prone to a variety of adverse events  on or off HD , 
ranging, for example, from infections to hypertension to bleeding to thromboembolism to 
acute ischemic cardiovascular emergencies,  even if they are apparently stable on chronic HD. 
A temporal and modest increase in blood pressure was observed in one study subject in the 
FIH study after xisomab 3G3 administration, and the event was deemed potentially related to 
the study drug.  
Xisomab  3G3 is a purified protein produced by [CONTACT_94988] a 
mammalian cell culture system, and these types of drugs can, occasionally and unpredictably 
evoke acute allergic reactions. Some ESRD patients develop chronic HD - and uremia -related 
moderate hemorrhagic diathesis or hemostasis impairment. Even though currently available 
data do not indicate a hemostatic function for the FXI/FXII interaction,  there remains a 
theoretical possibility of contact [CONTACT_84188] -mediated enhancement of hemostasis.  Thus,  the 
hemostatic safety of xisomab 3G3 in the complex conditions of ESRD and chronic HD is not 
yet known. The safety monitoring practices employed by [CONTACT_3181] (i.e., 12 -lead ECG, 
vital signs, blood pressure, clinical laboratory tests, AE question ing, vascular access site (AV 
fistula  or AV graft ) monitoring, and physical examination)  are adequate to protect the 
patient s’ safety and should detect all expected and unexpected treatment -emergent AEs  
(TEAEs) . In addition, the cohorts will be dosed in a sequential manner, starting with the 
lower dose level, Cohort  1.  
Patients undergoing heparin -free HD may be at higher risk of developi[INVESTIGATOR_790446]. Should this occur, site standard operating procedures will be followed to 
replace the clotted dialyzer and resume HD under the supervision of the PI.  It is important to 
note that replacement of the dialyzer cartridge is a safe procedure for the patient . While 
studies suggest that there is no risk o f thromboembolic complications should this occur, 
clotting of the dialyzer circuit could result in up to ~[ADDRESS_1089446] 
health benefit for study participants enrolled in this study is the free medical tests received at 
screening and d uring the study.  
  
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment 1 14June  2018 
 
Page 28 9 OBJECTIVES  AND ENDPOINTS  
9.1 Objectives  
The primary objective of this study is : 
• To assess the safety and tolerability of a single dose of xisomab  3G3 when injected  
through a port into the proximal (arterial) dialysis line immediately after initiation of a 
HD procedure in patients  with ESRD.  
The secondary objectives of this study are:  
• To assess the PD of a single dose of xisomab 3G3 when injected  through a port into t he 
proximal (arterial) dialysis line immediately after initiation of a HD procedure in 
patients  with ESRD.  
• To assess the efficacy  of a single dose of xisomab 3G3 on HD efficiency when injected  
through a port into the proximal (arterial) dialysis line immed iately after initiation of a 
HD procedure in patients  with ESRD . 
• To assess the PK of a single dose of xisomab 3G3 when injected  through a port into the 
proximal (arterial) dialysis line immediately after initiation of a HD procedure in 
patients  with ESRD . 
9.2 Endpoints  
Primary outcome  measure s: 
• The safety and tolerability of xisomab 3G3 will be evaluated versus pre -treatment  and 
placebo  by [CONTACT_790469], physical examination, vascular access site reaction, bleeding time, and 
changes in vital signs , ECGs, and clinical laboratory evaluations.  
Secondary outcome measures:  
• PD using d ose-dependency of drug potency , determined by [CONTACT_790470], and thrombus accumulation (assessed and ranked by [CONTACT_137459]) within the dialyzer cartridges and total protein accumulation in the HD filter  
after xisomab 3G3 -treatment versus pre -treatment  and placebo.  
• Efficacy on hemodialysis efficiency using BUN  and potassium levels befor e and after 
hemo dialysis, length of HD, measurement of urea removed by 3 hours of dialysis , and 
total dialysate urea  (single pool Kt/V  and URR) after xisomab 3G3 -treatment versus pre -
treatment and placebo . 
Other outcome measures:  
• PK parameters of xisomab 3G3 , calculated, as appropriate:  AUC0 -t, AUC0 -inf, 
AUC%extrap, Cmax, Tmax, Kel, t½, CL, and Vss. 
• Development of immunity or antibodies against xisomab 3G3 after drug exposure.  
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment 1 14June  2018 
 
Page 29 10 STUDY DESIGN  
10.1 Overall Study Design and Plan  
This is a phase 2, randomized, double -blind, placebo -controlled, single -dose study of 
xisomab 3G3 designed to evaluate the safety , efficacy /potency , and  PK at [ADDRESS_1089447] undergoing HD.  
A total of up to 24 adult male and female patients  will be enrolled; [ADDRESS_1089448] 50% of females and 
at least 30% of a race/ethnicity minority group.  Patients  will be enrolled into Cohort 1 or 
Cohort 2; cohorts will be dosed sequentially. Within a cohort, patients  will be randomized to 
active drug or placebo  as summarized below : 
Table 2: Cohort and Treatment Randomization  
Cohort  Treatment  Active: Placebo  Cohort Size  
1 Infusion dose of 0.25 mg/kg 
xisomab 3G3 or placebo  2:1 9-12 
2 Infusion dose of 0.5 mg/kg 
xisomab 3G3 or placebo  2:1 9-12 
This study includes a screening period of 28 days prior to checking -in to the clinical research 
unit on Day -8.  From Day  -7 (one week prior to dosing on Day 1)  through Day  -1, all 
patients  will undergo HD 3 times and will be assessed for all scheduled procedures and 
endpoints before and after each HD session as per the Study Events Flow Chart (Section  6).  
On Study Day 1, prior to dosing, patients  will undergo baseline me asurements followed by 
[CONTACT_214075] a regular HD procedure , consistently using only one type of dialyzer cartrid ge in 
each patient . Immediately after the start of blood perfusion, a single dose of xisomab  3G3 or 
matching placebo  will be injected through a  port into the flowing arterial blood in the 
proximal dialysis line . Patients  will continue to undergo HD procedures and scheduled 
assessments from Day 1 through Day 12. 
Study assessments will include physical examinations, vital signs, ECGs, clinical labo ratory 
tests, HD vascular access site (AV fistula  or AV graft ) reaction, antibody titer 
(immunogenicity), AEs, PD blood sampling (coagulation parameters) , and PK blood 
sampling to be performed throughout the study according to the Study Events Flow Chart 
(Section  6). On Days  -7, -5, and -3 and Days 1, 3, 5, and 12, b leeding time from the HD 
vascular  access site s on the AV fistula  or AV graft  (ladder or buttonhole technique) will be 
evaluated at the end of the HD session. The dialyzer cartridge will be rinsed and visually 
inspected at the end of the HD procedure and graded against a standardized visual assessment 
scale. After visual assessment, t he used and rinsed dialyzer cartridge will be frozen and sa ved 
for later retained content (deposited blood -derived material) analysis.  The number of dialyzer 
cartridges used for the HD session will be recorded.  
Patients  who withdraw prematurely from the study may be replaced at the discretion of the 
Investigator and Aronora, Inc. to ensure that up to 24 patients  (9 to 12 patients  per cohort) 
complete the study.  
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment 1 14June  2018 
 
Page 30 10.1.1  Confinement  and Follow -Up 
Patients  will be housed on Day -8, at the time indicated by [CONTACT_47365] , until after completion of 
study procedures  on Day 6  as indicated in the Study Events Flow Chart ( Section  6). Patients  
will return to the CRU as per the Study Events Flow Chart (Section  6) for additional HD 
sessions and study procedures. At all times, a patie nt may be required to remain at the CRU  
for longer at the discretion of the Principal Investigator (PI) or designee . 
All patients who received the study drug or placebo (including patients  who terminate the 
study early) will undergo follow -up procedures  at the CRU approximately [ADDRESS_1089449] scheduled study procedure as outlined in 
the Study Events Flow Chart ( Section  6). 
  
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment [ADDRESS_1089450] fulfill all of the following inclusion criteria to be eligible for participation in 
the study:  
1. ESRD maintained on stable outpatient HD re gimen , using an established (> 3 months) 
and normally functioning, regular flow, uninfected first mature AV fistula (or AV graft) 
and skin consistent with standard chronic HD access injuries, and HD stability  defined as 
Kt/V ≥ 1.2 within 3  months prior to screening  at a healthcare center for > [ADDRESS_1089451] 3 times per week for a minimum of 3  hours per dialysis session, 
using a complication -free well maintained AV fistula  (or AV graft) , expected and plan to 
continue this th roughout and for at least 3 months beyond  the study.   
3. Is capable of understanding the written informed consent, provides signed and witnessed 
written informed consent, and agrees to comply with protocol requirements and 
study -related procedures.  
4. Willing to be confined to the CRU for the duration of the study,  able to comply with all 
study -related requirements, and able to adhere to study restrictions and visit schedules.  
5. Male or female, between 18 and 80 years of age (inclusive) at the time of screening.   
6. BMI of ≥ [ADDRESS_1089452] undergone one of 
the following : 
• sterilization procedures at least 6 months prior to dosin g: 
• hysteroscopic sterilization;  
• bilateral tubal ligation or bilateral salpi[INVESTIGATOR_1656];  
• hysterectomy;  
• bilateral oophorectomy;  
or be postmenopausal with amenorrhea for at least 1 year prior to dosing and  
follicle -stimulating hormone (FSH) serum levels consistent with postmenopausal 
status  as per PI [INVESTIGATOR_214055].  
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment [ADDRESS_1089453] either be sterile (vasectomy with history of a negative sperm count 
following the procedure); practice total abstinence from sexual intercourse as the 
preferred lifest yle (periodic abstinence is not acceptable); use a male condom with any 
sexual activity; or agree to use a birth control method considered to be appropriate by [CONTACT_3786] (such as one of the methods identified above for female patients ) from the 
time of screening until [ADDRESS_1089454] not be enrolled in the study if they meet any of the following criteria:  
1. Documented history of acute vasoocclusive thrombotic event (acute coronary syndrome, 
stroke or transient ischemic attack, venous thromboembolic event ), or vascular access 
fistul a or AV graft failure  in the past 3 months.  
2. With the exception of unfractionated heparin during HD, c oncomitant or prior use of 
anticoagulant/antiplatelet agents (e.g., low molecular weight heparins, warfarin, 
api[INVESTIGATOR_3822], bivalirudin, ticagrelor, edoxaban, dabigatran, rivaroxaban, clopi[INVESTIGATOR_7745], 
prasugrel, ticlopi[INVESTIGATOR_5325], eptifibatide, tirofiban, dipyridamole, diclofenac, and all other 
NSAIDs) that may affect hemostasis for 2  weeks prior to check -in on Day -8 and 
throughout the study . 
3. Use of unfractionated hepari n for HD sessions from check -in on Day -8 and throughout 
the study.  
4. Any clinically significant (CS) concomitant disease or condition (including treatment for 
such conditions) that, in the opi[INVESTIGATOR_17439], could either interfere with the study drug , 
compr omise interpretation of study data , or pose an unacceptable risk to the patient . 
5. Any other CS abnormalities in laboratory test results at screening that would, in the 
opi[INVESTIGATOR_17439], increase the patient 's risk of participation, jeopardize complete 
participation in the study, or compromise interpretation of study data.  
6. Pregnant (positive pregnancy test) at screening or check -in on Day -8. If serum human 
chorionic gonadotropin (hCG) pregnancy test results are indeterminate, follow -up testing 
should be performed to determine eligibility.  
All female patients will not be pregnant and will have a negative pregnancy test at 
screening and check -in on Day -8, with the following exception: females receiving 
dialysis with an indeterminate pregnancy tes t result or persistently low hCG resulting in a 
false positive pregnancy test may be included in the study at the d iscretion of the PI. 
Postmenopausal patients  with a result outside the postmenopausal range or an 
indeterminate pregnancy test will undergo a dditional testing with FSH to confirm 
postmenopausal status prior to study enrollment.  
7. Treatment with another investigational drug or device study within 30  days (or 
5 half-lives, whichever is longer) prior to check -in on Day -8. 
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment [ADDRESS_1089455] established underlying inherited or acquired symptomatic bleeding 
disorders and/or are at risk for excessive bleeding per PI [INVESTIGATOR_214057] (e .g., gastroint estinal, intracranial), aside from minor bleeding from the puncture 
site on the AV fistula  or AV graft , which would be expected to occur during the dialysis 
procedure,  with the following values:  
• Platelet count < 100,000 cells/mm3 (if < 100,000 but >  75,000  cells/mm3, with 
permission of PI [INVESTIGATOR_214058] ) at screening   
• INR > 1.4  at screening  
• aPTT up to  1.[ADDRESS_1089456]  (if >1.2x ULN  up to < 1.[ADDRESS_1089457] , with permission of PI [INVESTIGATOR_458984] ) at screening  
• ALT or AST > [ADDRESS_1089458]  at screening  
• Total bilirubin > 1.[ADDRESS_1089459]  at screening  
• Hemoglobin concentration < 10 g/dL at screening  
10. Seated blood pressure < 90/40 mmHg at screening  and check -in on Day -8.  
11. Exclusion criteria for ECG  at screening and check -in on Day -8: 
Heart rate  < 45 and >  110 bpm  
QTcF interval  > 500 msec  
bpm = beats per minute; msec = milliseconds; QTcF = QT interval corrected using Fridericia’s 
formula  
• Any significant arrhythmia or conduction abnormality, (including but not specific to 
atrioventricular block [2nd degree or higher], Wolff Parkinson White syndrome [unless 
curative radio ablation therapy]) , which, in the opi[INVESTIGATOR_214059], could interfere with the safety for the individual patient . 
• Non-sustained or sustained ventricular tachycardi a (> 2 consecutive ventricular 
ectopic beats  at a rate of >  1.7/sec ond). 
12. History of a CS allergy to recombinant biologic drug , rodents, or a known sensitivity or 
idiosyncratic reaction to any compound present in xisomab 3G3, its related compounds, 
or any c ompound listed as being present in the study formulation.  
13. Participate in strenuous exercise from [ADDRESS_1089460] for drugs of abuse and/or positive alcohol test at screening or check -in on 
Day -[ADDRESS_1089461] 
based on a prescribed medication may be enrolled.  
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment [ADDRESS_1089462] at screening for hepatitis B surface antigen (HBsAg) or human 
immunodeficiency virus (HIV). If a patient  with ESRD has positive test results for 
hepatitis C virus (HCV) but liver function tests are otherwise not clinically significant, 
the patient  may be included at th e PI’s discretion.  
16. Receiving blood purification therapy other than HD.  
17. Any other reason that would render the patient  unsuitable for study enrollment at the 
discretion of the PI. 
11.3 Early Termination  of Patients  from the Study  
Patient  participation in this study may be discontinued for any of the following reasons:  
1. Occurrence of any medical condition or circumstance that exposes the patient  to 
substantial risk and/or does not allow the patient  to adhere to the requirements of the  
protocol.  
2. If the patient clots  the hemodialyzer twice they may be discontinued from the study  at the 
discretion of the PI. If the patient fully clots the hemo dialyzer , continuation of the patient 
in the study  will be at the PIs discretion.  
3. Any SAE, clinically significant AE, severe laboratory abnormality, intercurrent illness, or  
other medical condition that indicates to the PI [INVESTIGATOR_790447] . 
4. Patient 's decision to withdraw.  
5. Requirement of prohibited concomitant medicati on. 
6. Patient  failure to comply with protocol requirements or study related procedures.  
7. Termination of the study by [CONTACT_1034], FDA, Celerion, CRU , or other regulatory 
authorities .  
The clinical report will include reason(s) for patient  withdrawals as well as details relevant to 
the patient  withdrawal.  
If a patient  is withdrawn from the trial prior to study completion, the patient  will undergo all 
procedures scheduled for early termi nation as the situation allows (see the Study Events Flow 
Chart ( Section  6). Any patient  withdrawn due to an AE (whether serious or non -serious) or 
clinically significant abnormal laboratory test values will be evaluated by [CONTACT_978] [INVESTIGATOR_1660] a 
monitoring physician and will be treated and/or followed up until the symptoms or values 
return to normal or acceptable levels, as judged by [CONTACT_978] [INVESTIGATOR_1461].  
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment 1 14June  2018 
 
Page 35 11.4 Study R estrictions  
11.4.1  Prohibitions and Concomitant Medication  
Consumption of foods and beverages containing the following substances will be prohibited 
as indicated:  
• Xanthines/ caffeine: 48 hours prior to  dosing and throughout the period of sample 
collection (small amounts of caffeine derived from normal foodstuffs e.g., 
250 mL/8  oz./1 cup decaffeinated coffee or other decaffeinated beverage, per day, 
with the exception of espresso; 45  g/1.5  oz. chocolate bar, pe r day, would not be 
considered a deviation to this restriction);  
• Alcohol: 48  hours prior to  dosing and throughout the period of sample collection;  
Concomitant medications  will be listed, recorded, and allowed except for those listed as 
prohibited in the ex clusion criteria in Section  11.2. It is understood and will be considered 
that treatment with certain drugs or cessation of treatment with certain drugs (e.g., drugs for 
hypertension) may have adverse effects and could interfere with the evaluation of the 
primary outcome measures of the st udy.  
After randomization, acetaminophen (up to 2 g per 24  hours) may be administered , for fever 
or chronic pain control , at the discretion of the PI  [INVESTIGATOR_1461] . Administration of opi[INVESTIGATOR_790448].  
If deviations occur, the PI [INVESTIGATOR_214063] a case -by-case basis whether the patient  may continue participation in the study.  
11.4.2  Meals  
At the CRU, meals and/or snacks and fluids will be provided at appropriate times fol lowing 
check -in and throughout the study  as per the clinical site standard procedure . 
11.4.[ADDRESS_1089463] sports at any time from 48 hours prior to check -in on Day -8 and 
throughout the study . 
  
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment 1 14June  2018 
 
Page 36 12 TREATMENTS  
12.1 Treatments Administered  
A separate dosing manual will detail the drug preparation and treatment administration to be 
followed for this study.  
Xisomab 3G3 and matching placebo will be sup plied as sterile powder for injection via the 
IV route, upon reconstitution.  
Investigational materials will be provided by [CONTACT_790471] 3. 
Table 3: Identity of Investigational Products  
Product  Description  
Test Lyophilized xisomab 3G3 ( ∼15 mg/mL) sterile powder for injection in formulation buffer 
(8% sucrose, 10  mM histidine, 30  mM arginine HCl, 10  mM methionine, 80  ppm 
polysorbate 80, pH  5.4) 
Placebo  Lyophilized formulation buffer (8%  sucrose, 10  mM histidine, 30  mM arginine HCl, 
10 mM methionine, 80  ppm polysorbate 80, pH  5.4) 
 
An unblinded pharmacist  will be responsible for providing xisomab 3G3 or placebo to the 
blinded study personnel for administration via injection into the proximal hemodialysis line 
as per the randomization scheme.  
Patients  will be enrolled into Cohort 1 or Cohort 2. Within a coh ort, patients  will be 
randomized to active drug or placebo  as summarized  in Table 2. 
Patients  will receive a single infusion dose of 0.25 mg/kg xisomab 3G3 , 0.5 mg/kg 
xisomab  3G3, or matching placebo on Day [ADDRESS_1089464] be recorde d. 
The patient  weight recorded at check -in will be used to calculate the study drug dose.  
Should the need arise to change the infusion rate (i.e., due to an AE), changes to the infusion  
rate and the times at which those changes are made will be documented.  
12.[ADDRESS_1089465] be discontinued for the reasons described in 
Section  11.3. 
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment [ADDRESS_1089466] 50% of females and at 
least 30% of a race/ethnicity minority group. An attempt will also be made to approximately 
match key characteristics , including sex, average age , and weight per cohort.  
In each cohort, patient s will be randomized to receive either xisomab 3G3 or placebo  
maintai ning a 2:1 ratio   
If replacement patient s are used, the replacement patient  number will be 100 more than the 
original (e .g., Patient  No. [ADDRESS_1089467] Patient  No. 1).  
12.4 Blinding  
This is a double -blind, placebo -controlled study.  
12.4.1  Maintenance of Randomizati on 
A computerized randomization scheme will be created by a Celerion statistician and it shall 
be considered blinded as per the following : the randomization is available only to the CRU 
pharmacy staff that is  preparing the drug who will not be involved in any other aspect of the 
study including administration of the drug. It will not be made available to the Sponsor, 
patient s, or members of the staff responsible for the monitoring and evaluation of safety 
assessments.  
12.4.[ADDRESS_1089468] the Study Monitor or designee prior to breaking the blind. If breaking the blind is 
required because of a medical emergency, the treatment identity would be revealed by [CONTACT_978] 
[INVESTIGATOR_1461], for that patient  only. In the event that the emergency is one, in which it appears 
that the other patient s may be at imminent risk, the bl ind may be broken for all patient s dosed 
at that dose level. The unblinding will be properly documente d in the study file . 
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment [ADDRESS_1089469] the date and reason for 
code breaking.  
At the end of the stud y, envelopes will be retained or destroyed according to site procedures 
unless specified otherwise by [CONTACT_1034].  
12.4.3  Revealing of Randomization  
In the absence of a medical emergency, the blinded randomization for this study will not be 
revealed until all data are entered in the database, edits checks are performed, queries closed, 
CRFs signed by [CONTACT_978], and the database is officially locked.  
12.5 Trea tment Compliance  
Drug administration will be performed by a qualified designee (e.g., nurse). Before and after 
IV infusion, the qualified designee will visually inspect the syringe to ensure that the patient  
has received the entire dose. In the case of an  incomplete dosing  a few milliliters of blood 
could be drawn back into the dosing syringe and carefully reinjected to ensure administration 
of the complete dose; this will be reported.  
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment 1 14June  2018 
 
Page 39 13 STUDY ASSESSMENTS AND PROCEDURES  
The Study Events Flow Chart ( Section  6) summarizes the clinical procedures to be 
performed at each visit. Individual clinical procedures are described in detail below. 
Additional evalu ations/testing may be deemed necessary by [CONTACT_978] [INVESTIGATOR_50286]/or the 
Sponsor for reasons related to patient  safety.  
For this study, the primary assessment is the safety and tolerability. Safety will be determined 
by [CONTACT_63287], vit al signs, ECGs, clinical laboratory parameters, 
including but not limited to, hematology, serum chemistry profile, coagulation, urinalysis, 
vascular access site reaction, and AEs as outlined in the Study Events Flow Chart 
(Section  6). 
Any nonscheduled procedures required for urgent evaluation of safety concerns take 
precedence over all routine scheduled procedures.  
13.1 Screening  
Within 28  days prior to check-in on Day -8, medical history and demographic data, including 
name, sex, age, race, ethnicity, body weight  (kg), height  (cm), BMI  (kg/m2) and history of 
tobacco use will be re ported . Each patient  will have a physical examination, vital sign 
measurements (heart rate, blood pressure, temperature, and respi[INVESTIGATOR_697]), 12 -lead ECG, 
and the laboratory tests of hematological, coagulation, hepatic  and renal function and 
additional tests as noted in Section 13.2.7 . 
13.2 Safety and Tolerability Assessment s 
13.2.1  Physical Examination  
Full and abbreviated physical examinations will be performed as per Study Eve nts Flow 
Chart ( Section  6).  
Full physical examinations will include, at a minimum, assessment of the following systems: 
skin, head, ears, eyes, no se and throat, respi[INVESTIGATOR_2133], cardiovascular system, 
gastrointestinal system, neurological condition, blood and lymphatic systems, and the 
musculoskeletal system.  
Abbreviated physical examinations will include at the minimum, examination of respi[INVESTIGATOR_13521] y, 
cardiovascular, and gastrointestinal systems, with the option for further examination of 
additional systems as necessary based on reported symptoms/AEs.  
Symptom -driven physical examination may be performed at other times, if deemed necessary 
by [CONTACT_978] o r designee.  
Medical history will be recorded at screening.  
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment 1 14June  2018 
 
Page 40 13.2.2  Vital Signs  
Single measurements of body temperature, respi[INVESTIGATOR_697], blood pressure , and heart rate, 
will be measured as outlined in the Study Events Flow Chart ( Section  6). Additional vital 
signs may be taken at any other times, if deemed necessary.  
Vital signs  will be performed with patient s in a seated position  following a [ADDRESS_1089470] 
period , except when t hey are supi[INVESTIGATOR_1662] -reclined because of study procedures and/or AEs 
(e.g. nausea, dizziness) or if deemed necessary by [CONTACT_978]  [INVESTIGATOR_1461] . 
When scheduled postdose , vital signs will be performed within approximately 1 5 minutes of 
the scheduled time point .  
13.2.3  ECG Monitoring  
Single 12 -lead ECGs will be performed as outlined in the Study Events Flow Chart 
(Section  6). Additional ECGs may be taken at any  other times, if deemed necessary by [CONTACT_978]  
[INVESTIGATOR_1461] . 
ECGs will be performed with patient s in a semi-recumbent position  following a [ADDRESS_1089471] 
period . All ECG tracings will be reviewed by [CONTACT_978] [INVESTIGATOR_1461].  
When scheduled postdose , ECGs will be performed within approximately 20  minutes of the 
scheduled time point.  
13.2.4  Body Weight  
Body weight (kg) will be  measured daily  up to Day 6 , and before and after each HD  session , 
as outlined in the Study Events Flow Chart ( Section  6).  
13.2.5  Vascular Access  Site Reaction Assessment  
The monitoring of AEs will pay special attention to vascular access fistula  (or AV graft) site 
reacti ons. The preferred vascular access is an established AV fistula  (or AV graft) . Well 
established and reaction -free AV graft is an alternative, but less preferred access option, as it 
is more prone to complications. Patients who are hemodialyzed through catheters are not 
included in the study. Therefore, inspection of the  AV fistula  (or AV graft) and surrounding 
area will be performed. Any  new abnormal findings inconsistent with past skin injuries as 
expected in patie nts on chronic HD will be reported as AEs. AV f istula (or AV graft) site 
reactions will be evaluated as  outlined in the Study Events Flow Chart ( Section  6). Prior to 
HD, the AV fistula  (or AV graft) site will be  examined  for inflammation, infection, or flow 
abnormalities . When scheduled postdose, injection site examinations will be performed 
within  approximately 20 minutes after completion of the HD s ession . Reactions will be rated 
according to  the FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and 
Adolescent  Volunteers Enrolled in Preventive Vaccine Clinical Trials (FDA Guidance  2007 ) 
as follows:  
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment 1 14June  2018 
 
Page 41 Local Reaction  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
Pain  Does not interfere  with 
activity  Repeated use of 
non-narcotic pain  reliever 
> [ADDRESS_1089472] 
Erythema/Redness*  2.5 – 5 cm  5.1 – 10 cm  > 10 cm  
Induration/Swelling**  2.5 – 5 cm and does not 
interfere with activity  5.1 – 10 cm or interferes 
with activity  > 10 cm or prevents daily 
activity  
* In addition to grading the measured local reaction at the greatest single diameter, the measurement should 
be recorded as a continuous variable.  
** Induration/swelling should be evaluated and graded using the functional scale as well as the actual 
measurement.  
13.2.6  Bleeding of Access Site  
Evaluation of bleeding and bleeding time from the HD vascular access sites on the AV fistula 
or AV graft  using the ladder or buttonhole technique will be performed as per Study Events 
Flow Chart ( Section  6).  
Following hemodialysis, the needle will be removed from the vascular access site  and 
immediately followed by [CONTACT_214095] (i.e., gauze) . Pressure will be applied 
manually by a clinical associate  for 10  minutes before checking for evidence of bleeding 
around the dressing . If there is  still some bleeding, pressure will be applied back at the site 
for 5 minutes.  The site will then be checked again for evidence of bleeding; this procedure 
will be repeated every [ADDRESS_1089473].  
The t ime to clot will be recorded.  
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment 1 14June  2018 
 
Page 42 13.2.7  Clinical Laboratory Tests  
All tests listed below will be performed as outlined in the Study Events Flow Chart 
(Section  6). In addition, laboratory safety tests may be performed at various unscheduled 
time points, if deemed necessary by [CONTACT_978] [INVESTIGATOR_1461] .  
Hematology   Serum  Chemistry*  
• Hemoglobin  
• Hematocrit  
• Total and differential leukocyte 
count  
• Red blood cell count  
• Platelet count  
 
 
Coagulation  
• PT/INR  
• aPTT  
 
  • BUN  
• Bilirubin (total and direct)  
• ALP  
• AST 
• ALT  
• LDH  
• Albumin  
• Sodium  
• Potassium  
• Chloride  
• Glucose (fasting)  
• Creatinine**  
 
Urinalysis┼  Additional Tests  
• pH 
• Specific gravity  
• Protein***  
• Glucose  
• Ketones  
• Bilirubin  
• Blood***  
• Nitrite***  
• Urobilinogen  
• Leukocyte esterase***   • HIV test  
• HBsAg  
• HCV  
• Urine  or saliva  drug screen  
➢ Opi[INVESTIGATOR_858]  
➢ Amphetamines  
➢ Cocaine   
➢ Cannabinoids   
• Urine , breathalyzer , or saliva  alcohol screen  
• Serum pregnancy test  
(for females only)  
• FSH (for postmenopausal females only)  
 
* Serum chemistry tests will be performed after at least a  4-hour fast; however, in case of dropout s or 
rechecks, patient s may not have fasted for 4 hours  prior to  the serum chemistry sample is taken.  
** At screening, creatinine clearance will be  calculated using the Cockcroft -Gault formula.  
*** If urinalysis is positive for protein, blood, nitrite and/or leukocyte esterase, a microscopic examination 
(for red blood cells, white blood cells, bacteria, casts, and epi[INVESTIGATOR_1663]) will be performed.  
┼ For anuric patient s, urinalysis may not be performed . 
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment 1 14June  2018 
 
Page 43 13.2.8  Adverse Events  
[IP_ADDRESS]  Adverse Event Definition  
AE will be defined as any untoward medical occurrence during the study , associated or not 
with the use of xisomab 3G3 in the study patient s, whether or not considered drug related.  
TEAE is an AE that occ urs after administration of the study drug or placebo.  
A suspected adverse reaction means any AE for which there is a reasonable possibility that 
the drug caused the  AE. Reasonable possibility means there is evidence to suggest a causal 
relationship betwe en the drug and the AE.  
An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease temporally associated with the use of a medicinal 
(investigational) product, whether or not related to the study drug . (FDA Guidance, 2012 ) 
Prolonged aPTT is an expected pharmacodynamic effect of xisomab 3G3 and will, therefore, 
not be considered an AE.  
[IP_ADDRESS]  Monitoring  
Patient s will be monitored  for AE s from check -in through completion of the study . Patient s 
will be asked how they are feeling once per day during confinement and at each 
return/follow -up visit.  
AEs (whether serious or non -serious) and clinically significant abnormal laboratory test 
value(s) will be evaluated by  [CONTACT_978] [INVESTIGATOR_790449]/or followed up until the 
symptoms or value(s) return to normal, or acceptable levels, as judged by [CONTACT_978] [INVESTIGATOR_1461] .  
Treatment of serious adverse events  (SAEs) will be performed by a licensed medical 
provider, either at the CRU  or at a nearby [CONTACT_2360][INVESTIGATOR_9487] . Where appropriate, 
medical test(s) and/or examination(s) will be performed to document resolution of event(s). 
Outcome may be classified as resolved, improved, unchanged, worse, fatal , or unknown (lost 
to follow -up). 
[IP_ADDRESS]  Reporting  
All AEs that occurred during this clinical study (i.e., before, during, and after exposure of 
ESRD patients to xisomab 3G3) will be recorded. This design is to improve Sponsor ability 
to obtain reliab le initial information about drug safety yet reducing the number of study 
patient s needed to generate useful data.  
Adverse events and SAEs that are related to study participation (e.g., protocol -mandated 
intervention) will be recorded from the time the patient check -in until study  completion . All 
other AEs and SAEs will be recorded from Day -[ADDRESS_1089474] current MedDRA® available at Celerion.  
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment 1 14June  2018 
 
Page 44 The PI [INVESTIGATOR_790450]  (likely, 
probably, possibly, unlikely , or unrelated)  and severity . The date and time of onset,  time 
relationship to drug dosing, duration, and outcome of each event will be noted.  
Relationsh ip of AE:  
The relationship of each AE to the study drug will be assessed using the following  
definitions:  
Unrelated  
 • The adverse event must clearly be caused by [CONTACT_790472], or the 
study procedure/conditions  
• Definitely not related to d rug 
• Temporal sequence of an adverse event onset relative to  administration of drug not 
reasonable  
• Another obvious cause of an adverse event  
Unlikely  
 • Time sequence is unreasonable  
• There is another more likely cause for an adverse event  
Possibly  • Corresponds to what is known about the drug  
• Time sequence is reasonable  
• Could have been due to another equally, likely cause  
Probably  
 • Is a known effect of the drug  
• Time sequence from taking drug is reasonable  
• Ceases on stoppi[INVESTIGATOR_1478]  
• Cannot be reasonably explained by [CONTACT_790473]  • Is a known effect of the drug (e.g. listed in IB)  
• Time sequence from taking drug is reasonable  
• Event stops upon stoppi[INVESTIGATOR_21395], event returns upon restarting drug  
Note: Prolonged aPTT is an expected pharmacological effect of xisomab 3G3 and will, 
therefore, not be considered an AE.  
 
Severity of AE:  
Severity rating used during the study will be based on the toxicity grading scale tables  
present in the FDA (Center for  Biologics Evaluation and Research) toxicity grading scale for  
healthy volunteers 4 -point severi ty scale (Grade 1, 2, 3 and 4).  (FDA Guidance 2007 ) 
The following definitions for rating severity will be used for AEs not identified in the  
guidance:  
Mild (Grade 1)  
 The AE does not interfere with daily activity  
Moderate (Grade 2)  The AE interferes with daily activity, but no medical intervention is 
required  
Severe (Grade 3)  The AE prevents daily activity and requires me dical intervention  
Potentially Life -threatening 
(Grade  4) Emergency room visit or hospi[INVESTIGATOR_790451]23900 (3G3 -18-02), Final Protocol Amendment 1 14June  2018 
 
Page 45 [IP_ADDRESS]  Serious Adverse Event  
If any AEs are serious, as defined by [CONTACT_2165]  (FDA) Code of 
Federal Regulations  (CFR), Chapter 21, special procedures will be followed. All SAEs will 
be reported to the Sponsor via fax or e -mail within one working day of becoming aware of 
the event, whether or not the serious events are deemed drug -related. All serious event 
reporting  will adhere to 21  CFR  312.32 for Investigational New Drugs  (IND) and to the 
Guidance for Industry and Investigators: Safety Reporting Requirements for INDs and 
BA/BE, dated December 2012. The institutional review board  (IRB) will be notified of the 
Alert Reports as per FDA regulations.  
A SAE is any AE or suspected adverse reaction that in the view of either the PI (or designee)  
or Sponsor, results in  any of the following outcomes:  Death, a life -threatening adverse event, 
inpatient hospi[INVESTIGATOR_525232], a persistent or significant 
incapacity or substantial disruption of the ability to conduct normal life functions, or a 
congenital anomaly/birth defect. Important medical events that may not result in death, be 
life-threa tening, or require hospi[INVESTIGATOR_708], based upon 
appropriate medical judgment, they may jeopardize the patient or subject and may require 
medical or surgical intervention to prevent one of the outcomes listed in the above defin ition. 
Examples of such medical events include allergic bronchospasm requiring intensive 
treatment in an emergency room or at home, blood dyscrasias or convulsions that do not 
result in inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or dr ug abuse.  
Life-threatening is defined as an AE or suspected adverse reaction that in the view of the PI 
(or designee)  or Sponsor, its occurrence places the patient or subject at immediate risk of 
death. It does not include an AE or suspected adverse reaction that, had it occurred in a more 
severe form, might have caused death.  
Unexpected is defined as an AE or suspected adver se reaction that is not listed in the IB or is 
not listed at the specificity or severity that has been observed; or is not consistent with the 
risk information described in the general investigational plan or elsewhere in the current 
application, as amende d. 
If a SAE occurs to a patient  on this study, contact [CONTACT_78455]  3. 
13.3 Hemodialysis Procedure and Blood Clots in the Dialyzer Cartridge  
Patients will undergo hemodialysis 3 times a week as delineated in the Study Events Flow 
Chart ( Section  6). For each patient, the hemodialysis will last at least [ADDRESS_1089475] the clotted dialyzer and resume 
hemodialysis under the supervision of the PI, if appropriate.  It is important to note that 
replacement of the dialyzer cartridge is a safe procedure for the patient . While studies 
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment [ADDRESS_1089476] that there is no risk of thromboembolic complications should this occur, clotting of 
the dialyzer circuit could result in up to  ~228 mL of blood loss . 
The hemoglobin levels will be followed more closely.  
If the patient cl ots the hemodialyzer twice they may be discontinued from the study  at the 
discretion of the PI. If the patient fully clots the hemo dialyzer , the continuation of the patient 
in the study will be at the PIs discretion.  
13.4 Immunogenicity Assessment  
Blood sample s for immunogenicity assessment will be performed from the PK blood  
collection tubes as  delineated in the  Study Events Flow Chart ( Section  6). 
Instruction for blood sampling, collection, and processing will be provided separately.  
13.5 Pharmacodynamic Assessments  
Pharmacodynamic assessment will include evaluation of drug potency and efficiency of HD. 
For all patient s, PD assessments will be performed  at scheduled time points as delineated in 
the Study Events Flow Chart ( Section  6). 
Drug potency will be evaluat ed using the following PD m arkers:  
• thrombus accumulation  will be evaluated by a  visual inspection  of the dialyzer 
membrane at the end of HD procedures and by a gradation  using a standardized visual 
assessment scale  (e.g., Ronco et al ., 2017 );  
• total protein accumulation within the HD filter  will be evaluated using appropriate 
methods ; 
• coagulation parameters . 
Efficiency of HD will be assessed  by: 
• Blood  BUN  and potassium levels before and after dialysis ; 
• length of HD;  
• total dialysate urea  (measurement of BUN removed over 3 hours of dialysis ) will be 
computed;  
o single pool Kt/V  (where Kt = volume of fluid completely cleared of urea  
[K = dialyzer clearance (mL/min), t=time  of dialysis ] and V=volume of water a 
patient ’s body contains . 
o URR measur ed as the difference between urea pre -dialysis and post -dialysis 
expressed as a percentage . 
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment 1 14June  2018 
 
Page 47 13.6 Dialysate Analysis  
A 10 mL dialysate sample will be taken as delineated in the Study Events Flow Chart 
(Section  6). 
The samples will be sent to Aronora and will be stored for up to [ADDRESS_1089477] 
dosing for future analysis (e.g., xisomab 3G3 levels and or urea).   
Instruction for the sample collection, processing, and sample shipment will be provided  
separately.  
13.7 Pharmacokinetic Assessment s 
13.7.1  Blood Sampling and Processing  
For all patient s, blood samples for the determination of free (active) xisomab 3G3  will be 
collected at scheduled time points a s delineated in the Study Events Flow Chart ( Section  6). 
The sample times for PK collection are in relation to the start of infusion.  
Instruction for blood sampling, collection, processing, and sample shipment will be provided  
separately.  
Following completion of the samples analysis, leftover plasma samples will be shipped to the  
Sponsor, as per their instructions provided sep arately. Ad ditional analysis for exploratory  
purposes, including but not limited to factor XI activity, will be performed on leftover  plasma 
samples at the Sponsor’s discretion ; samples will be stored for up to [ADDRESS_1089478] dosing for future analysis . 
13.7.2  Plasma Pharmacokinetic Parameters  
The following PK parameters will be computed, as appropriate, for plasma free xisomab 3G3 
from the individual plasma concentrations using a non -compartmental approach:  
AUC0 -t: 
 The area under the plasma concentration -time curve, from time  [ADDRESS_1089479] measurable  non-zero concentration, as calculated by [CONTACT_758784].  
AUC0 -inf: The area under the plasma concentration -time curve from time  [ADDRESS_1089480] measurable plasma concentration to the 
elimination rate constant.  
AUC%extrap:  Percent of AUC0 -inf extrapolated, represented as (1  – AUC0 -
t/AUC0 -inf)*100.  
Cmax:  Maximum observed concentration.  
Tmax:  Time to reach Cmax. If the maximum value occurs at more than one 
time point, Tmax is defined as the first time point with this value.  
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment 1 14June  2018 
 
Page 48 Kel: Apparent first -order terminal elimination rate constant calculated from a 
semi -log plot of the plasma concentration versus time curve. The 
parameter will be calculated by [CONTACT_47390] -squares regression analysis 
using the maximum number of points in the terminal log -linear phase 
(e.g., three or more non -zero plasma concentrations).  
t½: Apparent first -order terminal eli mination half -life will be calculated as 
0.693/k el. 
CL: Apparent total plasma clearance calculated as  Dose/AUC0 -inf. 
Vss: Total apparent volume of distribution following single IV dose  
administration calculated as Vss = MRT x CL.  
MRT*: Mean residence time = AUMC0 -inf/AUC0 -inf (for IV infusion)  
AUCM0 -inf*: Area under the moment curve from time [ADDRESS_1089481] measurable 
concentration, = AUMC0 -t + [(tlast x Ct)/ Kel]+ Ct/(Kel)2 
* AUMC0 -inf and MRT values will be used for Vss calculation but will not be listed in the 
PK tables.  
Additional PK parameters  may be computed if deemed appropriate.  
Plasma concentrations below the limit of quantitation will be treated as missing for all PK 
calculations.  
No PK parameters will be calculated for patient s with 2 or fewer consecutive time points 
with detectable concentrations.  
No value for Kel, t½, AUC0 -inf, AUC%extrap, CL, and Vss, as appropriate,  will be reported 
for cases that do not exhibit a terminal log -linear phase in the concentration -time profile.  
Individual and mean plasma concentration time curves (both linear and log -linear) will be 
included in the final report.  
13.7.3  Analytical Method  
PK p lasma sample analysis will be performed using validat ed bioanalytical methods .  
Samples from patient s to be assayed are specified in Section  14.2. 
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment 1 14June  2018 
 
Page 49 13.8 Blood Volume Drawn for Study Assessments  
Table 4: Blood Volume during the Study  
Sample Type  Number of 
Time Points  Approximate 
Volume per Time 
Point * (mL)  Approximate Sample 
Volume Over Course 
of Study (mL)  
Screening laboratory safety tests (including 
hematology, serum chemistry, serology , and 
coagulation ), FSH (for postmenopausal 
female patient s only) and serum pregnancy 
(for female patient s only).  1 16  16 
On-study hematology  and serum 
chemistry( this includes serum pregnancy for 
female patient s only when scheduled at the 
same time)  4 12.5 60 
On-study coagulation (PT/INR and aPTT)   16 3.5 56 
On-study platelet count  only ** Up to 14 3.5 Up to 49 
On-study BUN  and potassium  only ** Up to 14 3.5 Up to 49 
Blood for P D (aPTT  only) ** Up to 17 2.7 Up to 45.9 
Blood for PK (free xisomab 3G3)  16 10 160 
Blood for Immunogenicity  2 *** *** 
Total Blood Volume (mL)→  Up to 435.9 † 
 
* Represents the largest collection tube that may be used for this (a smaller tube may be used).  
** Platelet count, BUN and potassium, and aPTT value will be taken from the hematology, serum 
chemistry, and coagulation sample, respectively, when these are scheduled to be collected at the same 
time. Samples will not be taken twice at a same timepoint  
*** Sample for immunogenicity will be taken from the PK sample tube. If this sample does not correspond 
with a PK  sample, an extra 10 mL of blood sample will be collected.   
† If additional safety, PK, or PD analysis is neces sary or if larger collection tubes are required to obtain 
sufficient plasma/serum for analysis, additional blood may be obtained (up to a maximum of 50 mL; 
this volume could be exceeded only with agreement of the PI [INVESTIGATOR_2394] a case -by-case basis).  
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment [ADDRESS_1089482] Operating Procedures, 
which are written based on the principles of GCP . 
14.1 Sample Size Determination  
The sample size chosen for this study was selected without statistical considerations. The 
sample size of up to 24 patient s in total (9 -12 per cohort with a ratio of 2:1 of active study 
drug:placebo) has been determined adequate to meet the study safety, t olerability, PD, and 
PK objectives.  
14.2 Population for Analyses  
Safety Population : All patient s who received the study drug (active or placebo)  will be 
included in the safety evaluations.  
PD Population : All patient s who received the study drug (active or placebo) and had at least 
one postdose measurement of any of the PD assessment will be included in the statistical 
analyses.  
PK Population : Samples from all patient s receiving the active drug  will be assayed even if  
the patient s do not complete the study. All patient s receiving the active drug  who comply 
sufficiently with the protocol and display an evaluable PK profile (e.g., exposure to 
treatment, availability of measurements and absence of major protocol violation s) will be 
included in the statistical analyses.   
14.3 Statistical Analyses  
Detailed methodology for summary and statistical analyses of the data collected in this study 
will be documented in a Statistical Analysis Plan (SAP). The SAP will be prepared by 
[CONTACT_790474]. This document may modify the plans outlined in 
the protocol; however, any major modifications of the primary endpoints definition and/or its 
analysis will also be reflected in a protocol amendment. Additional statistica l analyses other 
than those described in this section may be performed if deemed appropriate.  
14.3.1  Safety and Tolerability Analyses  
All safety data will be populated in the individual CRFs. All safety data will be listed by 
[CONTACT_4676] s. 
The placebo patient s from all cohorts will be pooled into a single placebo group for all 
summaries and presentations  
Dosing dates and times will be listed by [CONTACT_4676] . 
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment 1 14June  2018 
 
Page 51 Incidence and time of bleeding  from the HD access sites on the AV fistula (or AV graft) , as 
described in Section  13.2.[ADDRESS_1089483] current version of Medical Dictionary for Regulatory 
Activities (MedDRA®) available at Celerion and summarized by [CONTACT_3148]  (2 active dose 
levels and pooled placebo)  for the number of patient s reporting the treatment emerge nt 
adverse event (TEAE) and the number of TEAEs reported. A by -patient  AE data listing 
including verbatim term, coded term, treatment, severity, and relationship to study drug will 
be provided.  
Safety data including ECGs, vital signs assessments, clinical  laboratory results  and vascular 
access site reaction , will be summarized by [CONTACT_3148] (2 active dose levels and pooled 
placebo) and point of time of collection.  
Descriptive statistics using appropriate summary statistics will be calculated for quantitativ e 
safety data as well as for the difference to baseline, when appropriate. In addition, a shift 
table describing out of normal range shifts will be provided for clinical laboratory results.  
Concomitant medications will be listed by [CONTACT_790475] (2 active dose levels and 
pooled placebo) and coded using the most current version of WHO drug dictionary available 
at Celerion. Medical history will be listed by [CONTACT_4676] . 
14.3.2  Immunogenicity Analyses  
ADA titer will be reported and summarized descriptively.   
14.3.3  Pharmacodynamic Analyses  
Placebo patients from Cohort 1 and Cohort 2 will be pooled for analysis.   
The PD analysis will include assessments of drug potency and efficiency of HD. These will 
include change in aPTT, BUN, and potassium levels.  Change in thrombus accumulation, in 
total dialysate urea, URR, and Kt/V after xisomab  3G3 levels versus pre -treatment and 
placebo will also be evaluated.  Total protein accumulation within HD filter will be evaluated.  
The change from baseline in PD endpoin ts will be summarized by [CONTACT_3148] (2  active dose 
levels and pooled placebo) and at each scheduled time point using descriptive statistics . The 
baseline values are any value observed from Day -[ADDRESS_1089484] -baseline value minus the 
value at baseline.  
Additional analyses may be performed as deemed necessary upon review of the data.  
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment 1 14June  2018 
 
Page 52 14.3.4  Pharmacokinetic Analyses  
Values will be calculated for the plasma concentrations  and the PK parameters listed in 
Section  13.7.2  using appropriate summary statistics  to be fully outlined in the SAP .  
Pharmacokinetic parameter listings and statistical summaries will be generated separately for 
each cohort.  
Plasma concen tration data will also be displayed graphically on the linea r and semi -
logarithmic scales. F igures will be created to display mean and individual free xisomab 3G3 
concentration -time curves , stratified by [CONTACT_15994].  
Additional analyses may be performed as deemed necessary upon review of the data.  
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment [ADDRESS_1089485]  
This protocol will be reviewed by [CONTACT_1201], and the study will not start until the IRB has 
approved the protocol or a modification thereof. The IRB is constitu ted and operates in 
accordance with the principles and requirements described in the US Code of Federal 
Regulations (21  CFR  Part 56). The IRB is compliant to International Co uncil on 
Harmonisation (ICH) guidelines . 
15.1.[ADDRESS_1089486] of the Study  
This research will be carried out in accordance with the protocol, US Code of Federal 
Regulations, 21  CFR  Parts  50, 56, and 312, the ethical principles set forth in the Declaration 
of Helsinki, GCP, and the ICH harmonized tripartite guideline regarding 
GCP  (E6 Consolidated Guidance, April 1996).  
15.1.3  Patient  Information and Consent  
The purpose of the study, the procedures to be carried out and the potential hazards will be 
described to the patient s in non -technical terms. Patients will be required to read, sign and 
date an ICF summarizing the discussion prior to screening, and will be assured that they may 
withdraw from the study at any time without jeopardizing their medical care.  
Patient will be given a copy of their signed ICF. 
15.2 Termination of the Study  
Celerion /CRU  reserves the right to terminate the study in the interest of patient welfare.  
Sponsor reserves the right to suspend or terminate the study at any time . 
15.[ADDRESS_1089487] operating procedures are available for all activities performed at Cele rion relevant 
to the quality of this study. Designated personnel of Celerion will be responsible for 
implementing and maintaining quality assurance (QA) and quality control systems to ensure 
that the study is conducted, and that data are generated, documen ted and reported in 
compliance with the study protocol, GCP and Good Laboratory Practice requirements as well 
as applicable regulatory requirements and local laws, rules and regulations relating to the 
conduct of the clinical study.  
The Clinical Study Repo rt will be audited by [CONTACT_214108].  
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment 1 14June  2018 
 
Page 54 All clinical data will undergo a 100%  quality control check prior to clinical database lock. 
Edit checks are then performed for appropriate databases  as a validation routine using SAS® 
or comparable statistical program to check for missing data, data inconsistencies, data ranges , 
etc. Corrections are made prior to database lock.  
15.[ADDRESS_1089488] Access to Source Data/Documents  
The PI [INVESTIGATOR_214068], at all times, the primary records (i.e., source documents) of each 
patient’s data. Examples of source documents are laboratory reports, drug inventory, study 
drug label records, and CRFs that are used as the source.  
Celerion /CRU  will ensure that the Sponsor, IRB , and inspection  by [CONTACT_528763] -related sites, source 
data/documents, and reports for the purpose of monitoring , auditing (ICH[E6]  5.1.2  & 6.10)  
and inspection . In the event that other study -related monitoring should be done by [CONTACT_214109], they will be required to sign a confidentiality agreement prior to any monitoring and 
auditing.  
15.5 Drug Supplies, Packaging and Labeling  
The Sponsor will supply sufficient qua ntities of investigational  drug and matching placebo  to 
allow completion of this study.  The lot numbers, manufacture dates,  and expi[INVESTIGATOR_1659] ( if 
available) of the study drugs supplied will be recorded in the final report.  
The investigational product  and matching placebo  will be shipped to a designee at the CRU  
and must be stored in a pharmacy or locked and secured in a storage facility with controlled 
temperature. Humidity in the room will be monitored. The room is accessible only to those 
individuals a uthorized by [CONTACT_978].  
Records will be made of the receipt and dispensing of the study drugs  (active and placebo) 
supplied. At the conclusion of the study, any unused study drugs as well as original  
containers (even if empty), will be retained by [CONTACT_3452] , returned to the Sponsor  or 
designee , or destroyed, as per Sponsor instructions.  If no supplies remain, this fact will be 
documented in the pharmacy product accountability records.  
15.[ADDRESS_1089489]. These documents 
should be retained for a longer period however if required by [CONTACT_107245]. It is the responsibility of the Sponsor to 
inform the PI/Inst itution as to when these documents no longer need to be retained.  
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment 1 14June  2018 
 
Page 55 15.7 Report Format  
According to the ICH Harmonized Tripartite Guideline (Organization of the Common 
Technical Document for the Registration of Pharmaceuticals for Human Use M4 and the 
ICH M2 Expe rt Working Group), the final report will be written according to the 
ICH E3 Guideline (Structure and Content of Clinical Study Reports).  
15.8 Protocol Amendments  
Any amendments to the study protocol that seem to be appropriate as the study progresses  
will be d iscussed between Sponsor and the PI [INVESTIGATOR_1461]. All revisions and/or amendments  
to the protocol in writing must be approved by [CONTACT_1034], the PI [INVESTIGATOR_1461], and the IRB  
before implementation.  
15.[ADDRESS_1089490] party without the prior written consent of the Sponsor.  
The data generated by [CONTACT_117607]. This confidentia l information may be published only in collaboration with 
participating personnel from the Sponsor or upon Sponsor’s written consent to publish the 
article.  
CONFIDENTIAL  CA23900 (3G3 -18-02), Final Protocol Amendment 1 14June  2018 
 
Page 56 16 REFERENCES  
Caruana R. J., Raja M.R., and Bush J.V., et al. Heparin free dialysis: comparative data and 
results in high risk patients. Kidney Int. 1987;31:1351 -1355.  
Cronin R.E., and Reilly R.F. Unfractionated heparin for hemodialysis: still the best option. 
Semin Dial 2010;23(5):510 -515. Doi: 10.1111/j.1525 -139X.2010.[ZIP_CODE].x.  
FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent  
Volunteers Enrolled in Preventive Vaccine Clinical Trials. September 2007. Available  
online: 
http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInf
ormation/Guidances/Vacci nes/ucm091977.pdf  
FDA Guidance for Industry and Investigators: Safety Reporting Requirements for INDs  and 
BA/BE, dated December 2012. Available online at:  
http://www.fda.gov/downloads/Drugs/.../Guidances/UCM227351.pdf  
Lutz J., Jurk K., and Schinzel H.  Direct oral anticaoagulants in patients with chronic kidney 
disease: patient selection and special considerations . Int J Nephrol Renovasc Dis. 
2018;10:135 -143. doi: 10.2147/ijnrd.s105771  
Ronco C., Brendolan A., Nalesso F., et al . Prospective, r andomized, multicenter, controlled 
trial (TRIATHRON 1) on a new antithrombogenic hydrophilic dialysis membrane. Int J Artif 
Organs 2017;40(5):234 -9. 
Schwab S.J., Onorato J.J., Sharar L.R., et al. Hemodialysis without anticoagulation. One -year 
prospective T rial in Hospi[INVESTIGATOR_214069]. Am J Med. 1987;83:405 -410.  
Shen J.I., Mitani A.A., Chang T.I., et al.  Use and sa fety of heparin -free maintenance 
hemodialysis in the [LOCATION_003]. Nephrol Dial Transplant. 2013 Jun;28(6):1589 -602. doi: 
10.1093/nd t/gft067.  
Stamatiadis D.N., Helioti H., Mansour M., et al.  Hemodialysis for patients bleeding or at risk 
for bleeding, can be simple, safe and efficient  Clin Nephrol. 2004; 62(1) :29-34. 
Xisomab 3G3. Aronora, Inc. Investigator Brochure. Version Number 2; 24 May 2018 . 
 